Andrew E. Hendifar, MD, MPH
Curriculum Vitae
December 12, 2018
PROFESSIONAL CONTACT INFORMATION
8700 Beverly Blvd.
Los Angeles, CA 90048
Office: (310) 423-2217
Fax: (310) 967-8486
E-mail: [email protected]
EDUCATION
1996 – 1998 Student Research Fellow, National Institutes of Health
Primary Investigator: Robert Blumenthal, PhD
Influenza hemaglutinin mediated membrane fusion
Membrane Structure and Function, National Cancer Institute
May 1998 University of Maryland
College Park, MD
Degrees: BA-Philosophy; BS-Biochemistry
University of Maryland Honors Program Citation
May 2003 Tulane University School of Medicine
New Orleans, Louisiana
Doctor of Medicine
Master of Public Health, Health Systems Management
2003 – 2006 Resident, Department of Internal Medicine
University of Southern California
Los Angeles, California
2006 – 2007 Chief Resident, Internal Medicine
University of Southern California
Los Angeles, California
2007 – 2010 Fellow (Chief), Hematology and Oncology
University of Southern California
Los Angeles, California
Andrew E. Hendifar, MD 2
LICENSURE
NPI# 1649473414
License # A88863, California
DEA# BH9107524
BOARD CERTIFICATION
08/15/06 Internal Medicine
11/09/10 Hematology
11/16/11 Medical Oncology
PROFESSIONAL EXPERIENCE
2016 – present Medical Director, Pancreatic Cancer
Samuel Oschin Comprehensive Cancer Center
2012 – present Assistant Professor of Medicine
Medical Oncology Lead, Gastrointestinal Malignancies
David Geffen School of Medicine
Cedars Sinai Medical Center
Los Angeles, California
2003 Health Systems Management Externship
Supervisor: Dwayne Thomas, MD, Chief Executive Officer
Attended JCAHO surveys, and developed an employee retention
program while shadowing the CEO of the Medical Center of New
Orleans, LA.
2010 – 2012 Primary Investigator, Sarcoma, Pancreatic and Phase 1 Studies
Sarcoma Oncology Center
Santa Monica, California
Andrew E. Hendifar, MD 3
PROFESSIONAL ACTIVITIES
Committee Services
CSMC Committee Services
2014 – 2016 Member, Internal Review Board Committee
2014 – 2017 Member, Pharmacy and Therapeutics Committee
2014 – present Member, Cancer Committee
2014 – present Member, Gastrointestinal Cancer Committee, Southwest Oncology
Group (SWOG) Cancer Research Network
2014 – present Member, PAR-14-242 Microflora & Gastrointestinal (GI) Cancer
Committee
2016 – present Member, End of Life Committee
Other Committee Services
2005 – 2007 Vice President, Joint Committee of Interns and Residents
Service Employees International Union (SEIU) Healthcare
2016 – present Member, Diabetes Mellitus Chronic Pancreatitis Pancreatic Ductal
Adenocarcinoma (DM CP PDAC) Working Group, Consortium for
the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
(CPDPC)
2016 – present Supportive Care Medicine Chair, Precision Promise Consortium,
Pancreatic Cancer Action Network
2018 – present Steering Committee Member, Precision PromiseSM Clinical Trial
Consortium
2018 – present Member, Neuroendocrine Tumors Task Force (NET TF) of the
National Cancer Institute (NCI) Gastrointestinal Steering
Committee
2019 Scientific Advisory Committee (SAC) for MK7339-002: A Phase 2
Study of Olaparib Monotherapy in Participants with Previously
Treated, Homologous Recombination Repair Mutation (HRRm) or
Homologous Recombination Deficiency (HRD) Positive Advanced
Cancer
Andrew E. Hendifar, MD 4
Professional Associations/Society Memberships
2003 – present Member, American Society of Clinical Oncology
2015 – present Member, North American Neuroendocrine Tumor Society
(NANETS)
Editorial Services
2016 – present Editorial Board, Journal of Gastroenterology, Liver & Pancreatic
Diseases
2018 – present Editorial Board, Journal of Pancreatology
Consulting Activities
None
Community Services
April 2003 Volunteer, “Bridges to Communities.” Extended medical care to
rural Communities in Nicaragua.
2004 – 2007 Volunteer Physician, “Flying Sams.” An organization devoted to
extending medical services to migrant workers in Mexico.
2007 – 2008 Volunteer, ACP Leadership Conference
CSMC Conferences
2015 – 2016 Course Director: Los Angeles Carcinoid Neuroendocrine Tumor
Society & Caring for Carcinoid Foundation (LACNETS & CFCF)
Annual Los Angeles Neuroendocrine Tumor Patient Education
Conference
2016 Course Director, Pancreatic Cancer Conference
2018 Course Director, Gastrointestinal Cancer Conference
2018 Course Director, North American Neuroendocrine Tumor Society
(NANETS) Regional NET Education: The Multidisciplinary
Management of NET Cancers Conference
Andrew E. Hendifar, MD 5
Workshops
2013 UCLA CTSI Clinical and Translational Research Workshop
2014 UCLA CTSI K Award Workshop
Other CSMC Professional Activities
2012 – present Member, Multi-Disciplinary Pancreatic Cancer Team
2013 – 2014 CS-Link: ICD-10 Physician Champion
2013 – present Member, Pancreatic Cancer Research Team
2014 – present Lead, Gastrointestinal Oncology Algorithm Development
2014 – present Member, Multi-Disciplinary Neuroendocrine Team
2016 – present Medical Director, Pancreatic Cancer
2016 – present Lead, Gastrointestinal Disease Research Group
2019 Member, Center for Integrated Research on Cancer and Lifestyle
(CIRCL)
Other Professional Activities
2001 – 2003 Coordinator, Tulane-Louisiana State University (LSU) Choking
Prevention Program
Led organization involved with training service industry employees
choking rescue and basic life support. Trained over 600 employees
from establishments throughout the city.
2010 – 2012 Sarcoma Oncology Support Group Facilitator
HONORS AND SPECIAL AWARDS
1993 – 1998 Dean’s List, University of Maryland
1998 University of Maryland Honors Citation
1999 Aron’s MD/MPH Scholars Award: A scholarship awarded for
Master of Public Health
Andrew E. Hendifar, MD 6
2001 Nominee, Secretary’s Award for Innovations in Health
U.S. Department of Health and Human Services
2003 American Federation for Medical Research Student Recognition
Award
2005 First prize; American College of Physicians regional associate
abstract competition
2006 Brautbauer Teaching Award
2010 Top Doctors
2013 – present Super Doctors
RESEARCH GRANTS AND FELLOWSHIPS RECEIVED
Active/Ongoing
09/01/2015 – 08/31/2020 National Institute of Health, 1U01DK108314: Pathophysiology,
Epidemiology, and Prevention of Pancreatogenic Diabetes
Annual funding cost: $252,287
Role: Other significant contributor - consultant as needed, 0% effort
PIs: Stephen Pandol, MD and Mark Goodarzi, MD, PhD
01/01/2018 – 12/31/2018 Cedars-Sinai Precision Health: A Modified “Universal” Testing
Algorithm to Improve the Delivery of Genetic Care to Patients and
Families with Hereditary “High-Risk” Cancer Conditions
Total Cost: $150,000, 5% effort
PIs: Andrew Hendifar, MD and Megan P. Hitchins, PhD
08/01/2018 – 07/31/2021 Department of Defense Peer Reviewed Cancer Research Program
Translational Team Science Award, DoD CA170974: Sensitization
of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific
Drug Delivery
Annual direct costs: $233,383
Role: Consultant as needed, 0% effort
PIs: Leland Chung, PhD, Stephen Pandol, MD and James
Tomlinson, MD, PhD
Andrew E. Hendifar, MD 7
Inactive/Completed
None
Pending Grants
04/01/2019 – 03/31/2020 National Institute of Health, R21: A Prospective, Single Center,
Double Blind, Randomized, Crossover Feasibility Study of Oral
Ketamine versus Placebo for the Treatment of Anxiety in Patients
with Pancreatic Cancer
Direct costs/yr.: $150,000
Role: Co-investigator, 5% effort
PI: Scott Irwin, MD, PhD
RESEARCH FOCUS AND INTERESTS
Clinical Trials*
* Annual funding cost and % effort are unavailable for these clinical trials due to the nature of
funding and data availability. Costs are generated per patient activity. Number of patients
enrolled is provided as a proxy for effort on each trial. Information is provided as available.
02/2013 – 10/2019 Advanced Accelerator Applications, AAA-III-01: Multicenter,
Stratified, Open, Randomized, Comparator-controlled, Parallel
Group Phase III Comparing 177Lu-DOTA0-Tyr3-Octreotate to
Octreotide LAR in Inoperable, Progressive, Somatostatin Receptor
Positive, Midgut Carcinoid Tumors.
Primary investigator, no. of patients=18
08/2013 – 06/2023 Novartis Pharmaceuticals, SOM230B2412: An Open-label,
Multi-center Pasireotide Roll-over Protocol for Patients Who Have
Completed a Previous Novartis Sponsored Pasireotide Study and
are Judged by the Investigator to Benefit from Continued
Pasireotide Treatment.
Primary investigator, no. of patients=5
02/2014 – 01/2019 XBiotech, 2012-PT023: A Pivotal Phase III, Monotherapy Study to
Evaluate Survival Using MABp1 as a Monotherapy in Metastatic
Colorectal Cancer Patients with Cachexia.
Primary investigator, no. of patients=13
Andrew E. Hendifar, MD 8
03/2014 – present SWOG (Southwest Oncology Group), unfunded: Randomized,
Phase II Trial of Pazopanib vs Placebo in Patients with Progressive
Carcinoid Tumors.
Primary investigator, no. of patients=4
04/2015 – 04/2019 Cedars Sinai Medical Center (UCLA CTSI),
IIT2014-03-Hendifar-PanCax: Enteral Feeding for Pancreatic
Cancer Cachexia - A Longitudinal, Single Institution Study of
Enteral Feeding in Advanced Pancreatic Cancer Patients (Treatment
and Underlying Mechanisms of Pancreatic Cancer Cachexia).
Primary investigator, no. of patients=27
05/2015 – 05/2019 Halozyme, Inc., 50-PDA, 150 LUNG: Hyaluronan as a Predictive
and Prognostic Marker for Pancreatic Ductal Adenocarcinoma and
Lung Cancer. Primary investigator.
11/2015 – 01/2024 Alliance (Cooperative Group Study), EA2142: Randomized Phase
II Study of Cisplatin and Etoposide versus Temozolomide and
Capecitabine in Patients with Advanced G3 Non-Small Cell
Gastroenteropancreatic Neuroendocrine Carcinomas. Primary
investigator.
12/2015 – 12/2018 Novartis Pharmaceuticals, SOM230: A Proof of Concept and
Open-label Study to Test the Efficacy and Safety of Pasireotide in
Patients with Ecotopic ACTH-producing Tumors. Co-investigator.
PI: Alain Mita, MD.
03/2016 – 03/2019 Gilead Sciences, GS-US-370-1369: A Phase 1b Study Evaluating
Momelotinib Combined with Capecitabine and Oxaliplatin in
Subjects with Relapsed/Refractory Metastatic Pancreatic Ductal
Adenocarcinoma.
Primary investigator, no. of patients=5
04/2016 – 04/2019 Pharmacyclics, PCYC-1137: A Randomized, Multicenter,
Double-blind, Placebo-controlled, Phase 2/3 Study of the Brutons
Tyrosine Kinase Inhibitor Ibrutinib in Combination with
Nab-paclitaxel and Gemcitabine Versus Placebo in Combination
with Nab-paclitaxel and Gemcitabine, in the First Line Treatment of
Patients with Metastatic Pancreatic Adenocarcinoma.
Primary investigator, no. of patients=12
06/2016 – 06/2019 Merck, MK-3475-158-00: A Clinical Trial of Pembrolizumab
(MK-3475) Evaluating Predictive Biomarkers in Subjects with
Advanced Solid Tumors (KEYNOTE 158).
Primary investigator, no. of patients=9
Andrew E. Hendifar, MD 9
10/2016 – 10/2019 Halozyme, Inc., HALO-109-301: A Phase 3, Randomized,
Double-Blind, Placebo-Controlled, Multicenter of PEGylated
Recombinant Human Hyaluronidase (PEGPH20) in Combination
with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus
nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High
Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma.
Primary investigator, no. of patients=9
02/2017 – 08/2019 Alliance (Cooperative Group Study), EA2161: A Phase II Study of
MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic
Neuroendocrine Tumors (PNET).
Primary investigator, no. of patients=3
02/2017 – 02/2020 AstraZeneca, IIT-2016-01-Tuli-DURVARAD: A Phase 1/II Study
of Durvalumab and Stereotactive Ablative Body Radiotherapy in
Borderline Resectable and Locally Advanced Pancreatic
Adenocarcinoma.
Co-investigator, no. of patients=9. PI: Richard Tuli, MD, PhD.
05/2017 – 05/2020 Stemcentrx, Inc., SCRX001-006: An Open-Label Study of
Rovalpituzumab Tesirine in Subjects with Delta-Like Protein
3-Expressing Advanced Solid Tumors.
Primary investigator, no. of patients=9
06/2017 – 06/2020 Ipsen Pharmaceuticals, IIT2016-07-Hendlfar-OnFX: Phase I Study
of Onivyde (MM-398) and 5-Fluorouracil/Folinic Acid in
Combination with XilonixTM for Advanced Pancreatic Cancer
Patients with Cachexia (ONFX).
Primary investigator, no. of patients=11
10/2017 – 03/2020 AstraZeneca, D419CC00002: A Randomized, Open-label,
Multi-center Phase III Study of Durvalumab and Tremelimumab as
First-line Treatment in Patients with Unresectable Hepatocellular
Carcinoma (HIMALAYA). Primary investigator.
03/2018 – 03/2021 Xencor, Inc., XmAb18087-01: A Phase 1 Multiple Dose Study to
Evaluate the Safety and Tolerability of XmAb®18087 in Subjects
with Advanced Neuroendocrine and Gastrointestinal Stromal
Tumors. Primary investigator.
06/2018 – 07/2020 RGX-202-001: A Phase 1 Study of RGX-202-01, a Small Molecule
Inhibitor of the Creatine Transporter SLC6a8, with or Without
FOLFIRI, in Patients with Advanced Gastrointestinal Malignancies
with Select Expansion Cohorts. Primary investigator.
Andrew E. Hendifar, MD 10
Other Studies
08/2014 – present Cedars-Sinai Medical Center, unfunded: Treatment Outcomes in
Cholangiocarcinoma Patients. Primary investigator.
10/2014 – present Cedars-Sinai Medical Center, unfunded: Ethnicity and Cancer: A
Single Institution Analysis of Correlation Between Ethnicity and
Cancer. Primary investigator.
07/2015 – present Protocol No. 00039754: Assessment of Hyaluronan expression in
malignancy. Primary investigator.
06/2016 – present Protocol No. 00043427: Neuroendocrine Tumor. Primary
investigator.
01/2017 – present Protocol No. 00044138: Cardiac Complications in Carcinoids.
Primary investigator.
01/2017 – present Protocol No. 00042130: Malignant Pancreatic Neuroendocrine
Tumor Causing Low Blood Glucose Levels. Co-investigator.
03/2017 – present Protocol No. 00049091: PancPROMIS. Primary investigator.
Completed Clinical Trials*
02/2010 – 12/2015 Ipsen Pharmaceuticals, 2-55-52030-729: Extension Study of
Lanreotide Autogel in Entero-Pancreatic Endocrine Tumours.
Primary investigator.
05/2010 – 06/2015 Novartis Pharmaceuticals, CSOM230D2203: An Open-label,
Multicenter, Single-arm Study of Pasireotide LAR in Patients with
Rare Tumors of Neuroendocrine Origin. Primary investigator.
10/2010 – 08/2016 National Cancer Institute, S0518: Phase III Prospective
Randomized Comparison of Depot Octreotide plus Interferon Alpha
Versus Depot Octreotide plus Bevacizumab (NSC #704865) in
Advanced, Poor Prognosis Carcinoid Patients.
Primary investigator, no. of patients=22
05/2012 – 03/2015 National Cancer Institute, CALGB 80701: Randomized Phase II
Study of Everolimus Alone Versus Everolimus plus Bevacizumab
in Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
Primary investigator, no. of patients=7
Andrew E. Hendifar, MD 11
07/2012 – 03/2018 Novartis Pharmaceuticals, CBEZ235Z2401: Randomized Phase II
Study of BEZ235 or Everolimus in Advanced Pancreatic
Neuroendocrine Tumors. Primary investigator.
01/2013 – 09/2014 IIT_PancreasMRI: Improving Pancreas Radiotherapy Plans Using
Respiration-driven Anatomic Deformation: A Pilot Study.
Co-investigator, no. of patients=15. PI: Wensha Yang, PhD.
06/2013 – 12/2016 SWOG (Southwest Oncology Group), S1115: Randomized Phase 2,
AZD6244 Hydrogen Sulfate and MK-2206 vs mFOLFOX in
Metastatic Pancreatic Cancer.
Primary investigator, no. of patients=6
06/2013 – 09/2018 Halozyme Therapeutics, Inc., HALO-109-202: A Phase II,
Randomized, Study of PEGPH20 with Nab-paclitaxel plus
Gemcitabine Compared with Nab-paclitaxel plus Gemcitabine,
Stage IV Previously Untreated Pancreatic Cancer.
Primary investigator, no. of patients=15
07/2013 – 03/2017 Phase One Foundation, ITT2012-06-Tuli-Velgemrad: A Phase I
Study of Veliparib (ABT-888) in Combination with Gemcitabine
and Intensity Modulated Radiation Therapy in Patients with Locally
Advanced, Unresectable Pancreatic Cancer.
Co-investigator, no. of patients=34. PI: Richard Tuli, MD, PhD.
01/2014 – 12/2016 Eastern Cooperative Oncology Group, ECOG2211: Randomized,
Phase II, Study of Temozolomide or Temozolomide and
Capecitabine, Patients with Advanced Pancreatic Neuroendocrine
Tumors.
Primary investigator, no. of patients=13
05/2014 – 05/2017 Clovis Oncology, Inc., CO-338-023: Phase 2, Open-Label, Study of
Rucaparib for Patients with Pancreatic Cancer and BRCA Mutation.
Primary investigator.
06/2014 – 07/2018 Gilead Sciences, GS-US-370-1296: A Phase 2, Randomized,
Double-blind Study of Gemcitabine and Nab-paclitaxel Combined
with Momelotinib in Subjects with Previously Untreated Metastatic
Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding,
Lead-in Phase.
Primary investigator, no. of patients=8
Andrew E. Hendifar, MD 12
06/2014 – 07/2018 Gilead Sciences, GS-US-370-1296: A Phase 3, Randomized,
Double-blind Placebo-Controlled Study of Gemcitabine and
Nab-paclitaxel + Momelotinib in Subjects with Previously
Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded
by a Dose-finding, Lead-in Phase.
Primary investigator, no. of patients=8 (See previous Phase 2 study
above.)
07/2014 – 06/2016 UCLA CTSI grant number UL1TR000124, CTSI Seed Grant,
funded: Treatment and Underlying Mechanisms of Pancreatic
Cancer Cachexia. Primary Investigator.
01/2015 – 01/2017 Southwest Oncology Group, S1310: Randomized Phase II Trial of
Single Agent Mek Inhibitor Trametnib (GSK1120212) vs.
5-Fluorouracil or Capecitabine in Refractory Advanced Biliary
Cancer. Primary investigator.
02/2015 – 01/2017 Merck and Co., Inc., LKR141071: Quantitating the Expression of
PD-L1 in Resected Gastric and Gastroesophageal Adenocarcinoma.
Co-investigator. PI: Richard Tuli, MD, PhD.
05/2015 – 04/2016 Immunomedics, Inc., IMMU-107-04: An International,
Multi-Center, Double-Blind, Randomized, Phase III Trial of
90Y-Clivatuzumab Tetraxetan plus Low-dose Gemcitabine Versus
Placebo plus Low-Dose Gemcitabine in Patients with Metastatic
(Stage IV) Pancreatic Adenocarcinoma who Received at Least Two
Prior Treatments (PANCRIT-1). Primary investigator.
01/2016 – 08/2017 Cedars-Sinai Medical Center, IIT2015-10-Shinde-Biosens: The
Biosensor Study: Exploratory Study Evaluating the Use of
Wearable Biosensors and Patient Reported Outcomes (PROs) to
Assess Performance Status and Distress in Patients with Cancer.
Co-investigator. PI: Arvind Shinde, MD.
Research Roles
2016 – present Primary Investigator, Precision PromiseSM Clinical Trial
Consortium Site
Samuel Oschin Comprehensive Cancer Center
Cedars Sinai Medical Center
2012 – present Primary Investigator, Gastrointestinal Oncology Lead
Samuel Oschin Comprehensive Cancer Center
Cedars Sinai Medical Center
Andrew E. Hendifar, MD 13
1996 – 1998 Student Research Fellow, National Institutes of Health
Primary Investigator: Robert Blumenthal, PhD
Influenza hemaglutinin mediated membrane fusion
Membrane Structure and Function, National Cancer Institute
1999 – 2001 Clinical Investigator; Primary Investigator: Laura Dunbar MD, PhD
Hyponatremia in community acquired pneumonia
Emergency Medicine Department, Louisiana State University
2002 – 2003 Clinical Investigator; Primary investigator: Karen Desalvo MD,
MPH
Exposure to violence and its health consequences
Department of Medicine, Tulane University School of Medicine
2004 – 2010 Clinical Investigator; Primary Investigator: Heinz-Josef Lenz, MD
The role of hormone pathways in GI carcinogenesis
Prognostic markers for response and survival in stage 2 and 3 colon
cancer
Division of Oncology, University of Southern California
2010 – 2012 Primary Investigator
Focus on drug development and sarcoma research
Sarcoma Oncology Center
INVITED LECTURES AND PRESENTATIONS
1. Hendifar, Jubelin, Dunbar. Hyponatremia in community acquired pneumonia (CAP): Is it
truly marker for Legionella? 1999 American College of Emergency Physicians Research
Forum. Las Vegas, NV. October 11, 1999.
2. Hendifar, Fisher, DeSalvo. Health Correlates of Exposure to Violence. Society of General
Internal Medicine, 2003 Annual Regional Meeting. New Orleans LA.
3. Hendifar, Andrew. Clinical Trials for Soft Tissue Sarcomas. Cedars-Sinai Medical Oncology
Tumor Board. Los Angeles, CA. March 2, 2010.
4. Hendifar, Andrew. Overview of Sarcoma Oncology. Department of Orthopedics Grand
Rounds. University of Southern California. Los Angeles, CA. June 11, 2010.
5. Hendifar, Andrew. Novel Therapies for Sarcomas. 12th Annual Thoracic Oncology
Conference. University of California. San Francisco, CA. November 20, 2010.
6. Hendifar, Andrew. Updates on Pancreatic Cancer. Cedars-Sinai Medical Oncology Tumor
Board. Los Angeles, CA. December 10, 2010.
Andrew E. Hendifar, MD 14
7. Hendifar, Andrew. Sarcoma. Lunch and Learn. Cancer Wellness Community. Los Angeles,
CA. February 11, 2011.
8. Hendifar, Andrew. Targeting Mesothelioma: Veglin and Angiogenesis Inhibitors. 1st
International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma.
Santa Monica, CA. May 21, 2011.
9. Hendifar, Andrew. Sarcoma Oncology 2011: Updates and Treatment Advances. Division of
Oncology, University of Southern California. Los Angeles, CA. June 10 2011.
10. Hendifar, Andrew. Sarcoma Landscape Overview. Ziopharm Investigators Meeting. New
York, NY. July 23, 2011.
11. Hendifar, Andrew. Recent Advances in Hematology and Oncology. Brotman Medical Center.
Culver City, CA. October 6, 2011.
12. Hendifar, Andrew. Pancreatic Cancer and Il-6 Signaling. Hematology and Oncology Grand
Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. 2012.
13. Hendifar, Andrew. Pancreatic Cancer 2012. Grand Rounds. Cedars-Sinai Medical Center.
Los Angeles, CA. February 22, 2012.
14. Hendifar, Andrew. Challenges in Gastrointestinal Malignancies. Resident Lecture Series.
Cedars-Sinai Medical Center. Los Angeles, CA. January 16, 2013.
15. Hendifar, Andrew. Pancreas Cancer. Educational Lecture: Inpatient Specialty Program.
Cedars-Sinai Medical Center. Los Angeles, CA. April 2, 2013.
16. Andrew Hendifar, Richard Tuli, Nick Nissen. New Therapies and Advances in the Treatment
of Pancreatic Cancer. Cancer Support Community. Los Angeles, CA. July 16, 2013.
17. Hendifar, Andrew. Advances in Pancreatic Cancer. Cedars-Sinai Department of Medicine,
Grand Rounds. Los Angeles, CA. January 10, 2014.
18. Hendifar, Andrew. Grand Rounds. Cedars-Sinai Medical Center. Los Angeles, CA. January
22, 2014.
19. Hendifar, Andrew. New Approaches to Pancreatic Cancer. 21st International Symposium on
Pancreatic & Biliary Endoscopy. Cedars-Sinai Medical Center. Los Angeles, CA. January 31 -
February 2, 2014.
20. Hendifar, Andrew. Advances in Pancreatic Cancer. Brotman Medical Center. Culver City,
CA. April 21, 2014.
Andrew E. Hendifar, MD 15
21. Hendifar, Andrew. Advances in Pancreatic Cancer. Medicine Grand Rounds. Centinela
Freeman Hospital. Inglewood, CA. April 28, 2014.
22. Hendifar, Andrew. The New Face of Pancreatic Cancer. Advances in Care for the New
Millennium: 20th Anniversary BRCA Gene Symposium. Cedars-Sinai Medical Center. Los
Angeles, CA. September 13, 2014.
23. Hendifar, Andrew. Pancreatic Cancer 2014. Inpatient Hospitalist Lecture Series.
Cedars-Sinai Medical Center. Los Angeles, CA. September 23, 2014.
24. Hendifar, Andrew. Oncologic Emergencies. 3rd Year Inpatient Internal Medicine Student
Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. February 25,
2015.
25. Hendifar, Andrew. Carcinoid and Neuroendocrine Tumor Clinical Trials. Coronado Island
Library. Coronado, CA. March, 23, 2015.
26. Hendifar, Andrew. Managing Weight Loss in Cancer Patients. Henry Mayo Newhall
Hospital. Valencia, CA. March 26, 2015.
27. Hendifar, Andrew. Pancreatic Cancer 2015: New Breakthroughs on the Horizon. Valley
Presbyterian Hospital. Van Nuys, CA. April 06, 2015.
28. Hendifar, Andrew. Somatostatin Analog Therapy for the Treatment of Neuroendocrine
Tumors. Los Angeles Carcinoid and Neuroendocrine Tumor Support Group. Cedars-Sinai
Medical Center. Los Angeles, CA. May 12, 2015.
29. Hendifar, Andrew. Clinical Trials for Neuroendocrine Tumors. Los Angeles Carcinoid
Neuroendocrine Tumor Society & Caring for Carcinoid Foundation Annual Neuroendocrine
Tumor Patient & Caregiver Educational Conference. Cedars-Sinai Medical Center. Los
Angeles, CA. June 27, 2015.
30. Hendifar A, Hingorani S. High progression free survival and response rate in previously
untreated pancreatic cancer patients with high hyaluronan expression. 2015 European Society
of Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer. Barcelona, Spain.
July1, 2015.
31. Hendifar, Andrew. Cancer Cachexia. Hematology and Oncology Grand Rounds.
Cedars-Sinai Medical Center. Los Angeles, CA. October 13, 2015.
32. Hendifar, Andrew. Gastrointestinal Oncology: Cecal Cancer and TB/Pancreatic Cancer.
Samuel Oschin Comprehensive Cancer Institute (SOCCI) Multi-Disciplinary Tumor Board.
Cedars-Sinai Medical Center. Los Angeles, CA. October, 28, 2015.
Andrew E. Hendifar, MD 16
33. Hendifar, Andrew. Gastric Cancer. GI Fellows Lecture. Cedars-Sinai Medical Center. Los
Angeles, CA. December 1, 2015.
34. Hendifar, Andrew. Gastrointestinal Oncology: Pancreatic Cancers. Samuel Oschin
Comprehensive Cancer Institute (SOCCI) Multi-Disciplinary Tumor Board. Cedars-Sinai
Medical Center. Los Angeles, CA. January 6, 2016.
35. Hendifar, Andrew. Standard and Novel Chemotherapy for Pancreatic Cancer. 23rd
International Symposium on Pancreatic and Biliary Endoscopy. Cedars-Sinai Medical Center.
Los Angeles, CA. January 28, 2016.
36. Hendifar, Andrew. Advances in Pancreatic Cancer Therapy. Cancer Journal Club. Charles R.
Drew University of Medicine & Science. Los Angeles, CA. February 8, 2016.
37. Hendifar, Andrew. Results from the Netter-1 Study. Los Angeles Carcinoid Neuroendocrine
Tumor Society. Cedars-Sinai Medical Center. Los Angeles, CA. February 9, 2016.
38. Hendifar, Andrew. Pancreatic Cancer 2016. Educational Lecture: Inpatient Specialty
Program. Cedars-Sinai Medical Center. Los Angeles, CA. May 3, 2016.
39. Hendifar, Andrew. 1) Medical Oncology Advances for NETs and 2) PRRT: NETTER-1
Results 2016 & Beyond. 2016 Annual Los Angeles Neuroendocrine Tumor Patient Education
Conference. Cedars-Sinai Medical Center. Los Angeles, CA. June 25, 2016.
40. Hendifar, Andrew. Gastrointestinal Oncology: Metastatic Adenocarcinoma, Metastatic
Cancer and Pancreatic Cancer. Samuel Oschin Comprehensive Cancer Institute (SOCCI)
Multi-Disciplinary Tumor Board. Cedars-Sinai Medical Center. Los Angeles, CA. August 17,
2016.
41. Hendifar, Andrew. Lymphoma/Leukemia. 3rd Year Inpatient Internal Medicine Student
Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. September 7,
2016.
42. Hendifar, Andrew. The Road to Personalized Medicine: Featuring the Fenmore Lectureship
and The Redlich Lectureship: BRCA Mutated Pancreatic Cancer: A New Approach. 5th
Annual New Therapeutics in Oncology. Cedars-Sinai Medical Center. Los Angeles, CA.
November 4, 2016.
43. Hendifar, Andrew. Gastric Cancer. GI Fellows Lecture. Cedars-Sinai Medical Center. Los
Angeles, CA. December 1, 2016.
44. Hendifar, Andrew. Gastrointestinal Oncology: Pancreatic Cancers. Samuel Oschin
Comprehensive Cancer Institute (SOCCI) Multi-Disciplinary Tumor Board. Cedars-Sinai
Medical Center. Los Angeles, CA. January 11, 2017.
Andrew E. Hendifar, MD 17
45. Hendifar, Andrew. Lymphoma/Leukemia. 3rd Year Inpatient Internal Medicine Student
Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. May 1, 2017.
46. Hendifar, Andrew. Using Precision Medicine to Treat and Study Pancreatic Cancer.
Gastrointestinal Grand Rounds Conference. Cedars-Sinai Medical Center. Los Angeles, CA.
May 18, 2017.
47. Hendifar, Andrew. Pancreatic Cancer & Nutrition. Cancer Support Community Los Angeles.
Los Angeles, CA. August 4, 2017.
48. Hendifar, Andrew. Pancreatic Cancer. Henry Mayo Newhall Hospital. Valencia, CA.
September 7, 2017.
49. Hendifar, Andrew. Oncologic Emergencies. 3rd Year Inpatient Internal Medicine Student
Case-Based Didactic Session. Cedars-Sinai Medical Center. Los Angeles, CA. October 30,
2017.
50. Hendifar, Andrew. IM/Hematology/Oncology: Neuroendocrine Carcinoma. Samuel Oschin
Comprehensive Cancer Institute (SOCCI) Molecular Tumor Board. Cedars-Sinai Medical
Center. Los Angeles, CA. November 1, 2017.
51. Hendifar, Andrew. Harnessing Her2/Neu, BRAF and MSI. 6th Annual Experimental
Therapeutics in Oncology: The Road to Personalized Medicine. Cedars-Sinai Medical Center.
Los Angeles, CA. November 4, 2017.
52. Hendifar, Andrew. Peptamen for Weight Loss. 10th International Society on Sarcopenia,
Cachexia and Wasting Disorders (SCWD) Conference on Cachexia, Sarcopenia & Muscle
Wasting. Rome, Italy. December 10, 2017.
53. Hendifar, Andrew. The Quest to Win Through Science in Pancreatic Cancer from
Sequencing Current Options to Testing Novel Approaches Dear Members. 2018 ASCO
Gastrointestinal Cancers Symposium. San Francisco, CA. January 19, 2018.
54. Hendifar, Andrew. Gastrointestinal Oncology: Gastrointestinal Cancer, Ectopic Producing
ACTH and Pancreatic Cancer. Samuel Oschin Comprehensive Cancer Institute (SOCCI)
Multi-Disciplinary Tumor Board. Cedars-Sinai Medical Center. Los Angeles, CA. March 7,
2018.
55. Hendifar, Andrew. Pancreas Cancer 2018. VA Sepulveda/Cedars-Sinai Medical Center
Grand Rounds. VA Sepulveda Ambulatory Care Center. North Hills, CA. March 8, 2018.
56. Hendifar, Andrew. Managing Symptoms—Carcinoid Syndrome & More. 2018 Annual Los
Angeles NET Patient Education Conference. UCLA. Los Angeles, CA. May 19, 2018.
57. Hendifar, Andrew. Pancreas Cancer 2018. Hematology/Oncology Grand Rounds.
Cedars-Sinai Medical Center. Los Angeles, CA. July 24, 2018.
Andrew E. Hendifar, MD 18
58. Hendifar, Andrew. Neoplasms of the Stomach and Duodenum. GI Fellows Core Lecture.
Cedars-Sinai Medical Center. Los Angeles, CA. November 6, 2018.
TEACHING ACTIVITIES
1. 03/2013 Consult Service Attending Hematology and Oncology
2. 10/2013 Consult Service Attending Hematology and Oncology
3. 2013 – present Clinic Attending for Medical Students and Residents
4. 2013 – present Journal Club for Gastrointestinal (GI) Oncology
5. 10/2014 Surgical Oncology Fellowship Rotation in Gastrointestinal (GI)
Oncology, Fellow Jenny Hong
6. 2015 – present 3rd Year Inpatient Internal Medicine Student Case-Based Didactic
Sessions
7. 2015 – present Carcinoid and Neuroendocrine Tumor Board Meeting
8. 2015 – present Pancreatic Cancer Research Meeting
9. 06/05/2017 – 08/24/2017 Summer Intern Isaac Lapite
10. 06/27/2017 – 06/13/18 Intern Michelle Guan
11. 11/6/17 – 11/10/17 Surgical Oncology Fellowship Rotation in Gastrointestinal (GI)
Oncology, Fellow Jamie Green, MD
12. 12/01/17 – 02/27/18 Long Beach Polytechnic High School PACE Program (advanced
studies) Interns: Thomas Crahan and Jimmy Giles
MENTEES
Attendings
1. Patrick Yaffee, MD 07/2013 – 01/2015, one on one mentoring
Projects: Rectal cancer review, Th-302 in advanced soft tissue sarcoma
2. Carlyn Rose Tan, MD 01/2013 – 2016, one on one mentoring,
Projects: Pancreatic cancer cachexia, EGFRI inhibitors and colorectal cancer
Andrew E. Hendifar, MD 19
3. Arsen Osipov, MD 07/2013 – present, one on one mentoring
Projects: Margin distance and lymph node stations in resected pancreatic cancer,
retrospective review of breast cancer gene (BRCA) mutated pancreatic cancer at Cedars
Sinai
Residents
4. Jasleen Khanuja, MD 01/2014 – 01/2016, one on one mentoring
Projects: Ethnicity and pancreatic cancer
5. Ingrid He, MD 08/17 – present, one on one mentoring
Projects: Tog 0631
6. Varun Roy, MD 09/17 – present, one on one mentoring
Projects: Portal hypertension in pancreatic cancer patients
PUBLIC RELATIONS
Media Partnerships
1. Hendifar, Andrew. Video Interview: PEGPH20 Survival Impact in High Hyaluronan
Pancreatic Cancer. OncLive, Oncology Specialty Group, Cranbury, NJ. Interviewer: Laura
Martin. 2015 ESMO World Congress on Gastrointestinal Cancer. Barcelona, Spain. July 1,
2015.
2. Hendifar, Andrew. Interview: I’m Drawn to Tough Challenges. Pancreatic Cancer Action
Network (PanCAN), Manhattan Beach, CA. April 26, 2017.
3. Hendifar, Andrew. Video Interview: “Breaking the barrier: a new therapeutic approach to the
treatment of pancreatic ductal adenocarcinoma.” Touch Medical Media, touch ONCOLOGY,
London. Interviewer: Joanna Brockley, Associate Editor of European Oncology and
Haematology. 2017 ASCO Annual Meeting. Chicago, IL. June 3, 2017.
4. Hendifar, Andrew. Video Interview: HALO-202 Study in Metastatic Pancreatic Ductal
Adenocarcinoma. OncLive, Oncology Specialty Group, Cranbury, NJ. Interviewer: Angelica
Welch, Assistant Web Editor. 2017 ESMO World Congress on Gastrointestinal Cancer.
Barcelona, Spain. June 29, 2017.
5. Hendifar, Andrew. Video Interview: Current Treatment Landscape in Pancreas Cancer.
OncLive TV, Cranbury, NJ. July 13, 2017.
6. Hendifar, Andrew. Cancer Radio Spot Recording. 740 Sound Design. Los Angeles, CA.
September 8, 2017.
Andrew E. Hendifar, MD 20
7. Hendifar, Andrew. Video Interview: Molecular Classification of Neuroendocrine Tumors:
Clinical Experience with the 92-Gene Assay in 24,000 Cases. OncLive®, Cranbury, NJ.
Interviewer: Gina Columbus, Managing Editor, OncLive®. North American Neuroendocrine
Tumor Society (NANETS) 10th Annual Symposium. Philadelphia, PA. October 19, 2017.
8. Hendifar, Andrew. Video Interview: Molecular Classification Helps Pinpoint Subtype,
Origin of NETs. MDLinx, M3, Fort Washington, PA. Emergency Medicine. Interviewer: Liz
Meszaros, Sr. Medical Writer/Editor. North American Neuroendocrine Tumor Society
(NANETS) 10th Annual Symposium. Philadelphia, PA. October 19, 2017.
9. Hendifar, Andrew. Taped Interview: What’s on Your Mind? News Talk WMBS 590 AM /
101.1 FM. Host: Bill Madden. Estimated audience reach: 203,550 listeners. Pittsburgh, PA.
November 15, 2017.
10. Hendifar, Andrew. Taped Interview: Focus on Health Segment. News WGRT 102.3 FM.
Host: Cathie Martin, News Director. Estimated audience reach: 280,000 listeners. Detroit, MI.
November 15, 2017.
11. Hendifar, Andrew. Live Interview: The Good News. WDJC 93.7 FM. Host: Angie Austin.
Estimated national audience reach: 694,000 listeners. Birmingham, AL. November 15, 2017.
12. Hendifar, Andrew. Taped Interview. La Crosse Talk WIZM 1410 AM / 92.3 FM. Host: Mike
Hayes. Estimated audience reach: 197,750 listeners. La Crosse, WI. November 15, 2017.
13. Hendifar, Andrew. Taped Interview. Real Talk WSRB 106.3 FM / WYCA 102.3 FM. Host:
Debra Rhodes-Pettigrew. Estimated audience reach: 463,000 listeners. Chicago, IL. November
15, 2017.
Press Releases
1. Fitness trackers prove helpful in monitoring cancer patients. Los Angeles, CA: Cedars-Sinai
Medical Center Newsroom; July 24, 2018. Available at:
https://www.cedars-sinai.org/newsroom/fitness-trackers-prove-helpful-in-monitoring-cancer-
patients/. Accessed July 24, 2018.
2. Fitness trackers can help monitor cancer patients. Boston, MA: CBS; July 26, 2018. Available
at: https://boston.cbslocal.com/2018/07/26/fitness-trackers-monitor-cancer-patients/.
Accessed July 27, 2018.
3. Cedars-Sinai says fitness trackers prove helpful in monitoring cancer patients. Los Angeles,
CA: Los Angeles Tech News; July 26, 2018. Available at:
https://latechnews.org/cedars-sinai-says-fitness-trackers-prove-helpful-in-monitoring-cancer-
patients/. Accessed July 27, 2018.
Andrew E. Hendifar, MD 21
4. Fitness trackers help monitor cancer patients. Hematology Times; July 25, 2018. Available at:
https://www.hematologytimes.com/section/related-issues/article/fitness-trackers-help-monito
r-cancer-patients/. Accessed July 27, 2018.
5. Fitness trackers could aid cancer patients. R&D Magazine; July 25, 2018. Available at:
https://www.rdmag.com/article/2018/07/fitness-trackers-could-aid-cancer-patients. Accessed
July 27, 2018.
6. Fitness trackers can benefit people in cancer treatment. HealthCentral; July 25, 2018.
Available at:
https://www.healthcentral.com/article/fitness-trackers-can-benefit-people-in-cancer-treatment.
Accessed July 27, 2018.
7. Fitness trackers helpful for cancer assessments. LabRoots; July 25, 2018. Available at:
https://www.labroots.com/trending/technology/12200/fitness-trackers-helpful-cancer-assess
ments. Accessed July 27, 2018.
8. Fitness trackers help assess quality of life, daily functioning during treatment: study. Los
Angeles, CA. Xinhua; July 25, 2018. Available at:
http://www.xinhuanet.com/english/2018-07/25/c_137346072.htm. Accessed July 27, 2018.
9. In patients with advanced cancer, fitness trackers may help assess performance status. AJMC;
August 1, 2018. Available at:
https://www.ajmc.com/focus-of-the-week/in-patients-with-advanced-cancer-fitness-trackers-
may-help-assess-performance-status. Accessed August 1, 2018.
10. Fitness trackers prove useful in supervising cancer patients. New York, NY: Healthcare News
24; July 27, 2018. Available at:
http://healthcarenews24.com/1125/fitness-trackers-prove-useful-in-supervising-cancer-patien
ts/. Accessed August 1, 2018.
BIBLIOGRAPHY/PUBLICATIONS
Research Papers (Peer-Reviewed)
A. Research Papers – Peer Reviewed
1. Hendifar, El-Khoueiry, Lenz. Targeting colorectal cancer. Hospital Pharmacy Europe. 2005
May/June;(20):50-53.
2. Hendifar AE, Johnson D, Arkfeld DG. Myositis ossificans: a case report. Arthritis Rheum.
2005 Oct 15;53(5):793-5. PubMed PMID: 16208662.
3. El-Khoueiry, Hendifar, Lenz. “The medical treatment of metastatic colorectal cancer.”
Oncology Special Edition. 2005;(8):211-216.
Andrew E. Hendifar, MD 22
4. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM,
Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate
synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer.
Pharmacogenet Genomics. 2008 Feb;18(2):161-8. doi:10.1097/FPC.0b013e3282f4aea6.
PubMed PMID: 18192902.
5. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE, Husain H, Gordon MA,
Nagashima F, Chang HM, Lenz HJ. Polymorphisms in VEGF and IL-8 predict tumor
recurrence in stage III colon cancer. Ann Oncol. 2008 Oct;19(10):1734-41. doi:
10.1093/annonc/mdn368. Epub 2008 Jun 11. PubMed PMID: 18550579.
6. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y,
Zhang W, Lenz HJ. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist
associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009
Feb;19(2):95-102. doi: 10.1097/FPC.0b013e32831a9ad1. PubMed PMID: 18987561.
7. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, Ning Y, Zhang W, Lenz HJ. Gender
disparities in metastatic colorectal cancer survival. Clin Cancer Res. 2009 Oct
15;15(20):6391-7. doi: 10.1158/1078-0432.CCR-09-0877. Epub 2009 Sep 29. PubMed PMID:
19789331.
8. Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y,
Groshen S, Lenz HJ. Survival of metastatic gastric cancer: significance of age, sex and
race/ethnicity. J Gastrointest Oncol. 2011 Jun;2(2):77-84. doi:
10.3978/j.issn.2078-6891.2010.025. PubMed PMID: 22811834.
9. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C,
Menendez LR. A meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012;2012:704872. doi: 10.1155/2012/704872. Epub 2012 Mar 18. PubMed PMID:
22550423.
10. Andrew E Hendifar, Sant P Chawla. Pazopanib for nonadipocytic, non-GIST soft tissue
sarcomas. Community Oncology. 2012 Nov. 9(11):332–333.
11. Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YYM. Results of a
phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma
receiving doxorubicin and ifosfamide. BMC Cancer. 2013 Mar 16;13:121. doi:
10.1186/1471-2407-13-121. PubMed PMID: 23497336.
12. Gong J, Delioukina ML, Hendifar AE. A Rare Case of Primary Gastric HIV-Associated
peripheral t-cell lymphoma: relapsed disease treated with pemetrexed. World J Oncol. 2013
Oct;4(4-5):217-220. doi: 10.4021/wjon708w. Epub 2013 Sep 27. PubMed PMID: 29147360.
Andrew E. Hendifar, MD 23
13. Blay JY, Leahy MG, Nguyen BB, Patel SR, Hohenberger P, Santoro A, Staddon AP, Penel N,
Piperno-Neumann S, Hendifar A, Lardelli P, Nieto A, Alfaro V, Chawla SP. Randomised
phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in
translocation-related sarcomas. Eur J Cancer. 2014 Apr;50(6):1137-47. doi:
10.1016/j.ejca.2014.01.012. Epub 2014 Feb 7. PubMed PMID: 24512981.
14. Chawla SP, Cranmer LD, Van Tine BA, Reed DR, Okuno SH, Butrynski JE, Adkins DR,
Hendifar AE, Kroll S, Ganjoo KN. Phase II Study of the safety and antitumor activity of the
hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced
soft tissue sarcoma. J Clin Oncol. 2014 Oct 10;32(29):3299-306. doi:
10.1200/JCO.2013.54.3660. Epub 2014 Sep 2. PubMed PMID: 25185097.
15. Chawla SP, Chua VS, Hendifar AF, Quon DV, Soman N, Sankhala KK, Wieland DS, Levitt
DJ. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015 Feb
15;121(4):570-9. doi: 10.1002/cncr.29081. Epub 2014 Oct 13. PubMed PMID: 25312684.
16. Yang W, Reznik R, Fraass BA, Nissen N, Hendifar A, Wachsman A, Sandler H, Tuli R.
Dosimetric evaluation of simultaneous integrated boost during stereotactic body radiation
therapy for pancreatic cancer. Med Dosim. 2015 Spring;40(1):47-52. doi:
10.1016/j.meddos.2014.09.001. Epub 2014 Oct 22. PubMed PMID: 25445989.
17. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya
CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A,
Collisson EA. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas.
Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun
24. PubMed PMID: 26109333.
18. Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic
cancer. Mol Clin Oncol. 2016 Mar;4(3):315-325. Epub 2015 Dec 18. PubMed PMID:
26998283.
19. Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, Li Q, Tuli R. Influence of
body mass index and albumin on perioperative morbidity and clinical outcomes in resected
pancreatic adenocarcinoma. PLoS One. 2016 Mar 25;11(3):e0152172. doi:
10.1371/journal.pone.0152172. eCollection 2016. PubMed PMID: 27015568.
20. Osipov A, Naziri J, Hendifar A, Dhall D, Rutgers JK, Chopra S, Li Q, Tighiouart M,
Annamalai A, Nissen NN, Tuli R. Impact of margin status and lymphadenectomy on clinical
outcomes in resected pancreatic adenocarcinoma: implications for adjuvant radiotherapy. J
Gastrointest Oncol. 2016 Apr;7(2):239-47. doi: 10.3978/j.issn.2078-6891.2015.109. PubMed
PMID: 27034792.
Andrew E. Hendifar, MD 24
21. Pishvaian MJ, Joseph Bender R, Matrisian LM, Rahib L, Hendifar A, Hoos WA, Mikhail S,
Chung V, Picozzi V, Heartwell C, Mason K, Varieur K, Aberra M, Madhavan S, Petricoin E
3rd, Brody JR. A pilot study evaluating concordance between blood-based and
patient-matched tumor molecular testing within pancreatic cancer patients participating in the
Know Your Tumor (KYT) initiative. Oncotarget. 2016 Nov 8;8(48):83446-83456. doi:
10.18632/oncotarget.13225. eCollection 2017 Oct 13. PubMed PMID: 29137355.
22. Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE,
Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD,
Hochster HS. Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients
with metastatic pancreatic cancer after prior therapy: SWOG S1115 Study Randomized
Clinical Trial. JAMA Oncol. 2016 Dec 15. doi: 10.1001/jamaoncol.2016.5383. [Epub ahead of
print] PMID: 27978579.
23. Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, Fan X. A clinicopathological
study of malignant insulinoma in a contemporary series. Pancreas. 2017 Jan;46(1):48-56.
PMID: 27984486.
24. Gong J, Sachdev E, Robbins LA, Lin E, Hendifar AE, Mita MM. Statins and pancreatic
cancer. Oncol Lett. 2017 Mar;13(3):1035-1040. doi: 10.3892/ol.2017.5572. Epub 2017 Jan 4.
PubMed PMID: 28454210.
25. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke
MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R,
Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J,
Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T,
Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase
3 Trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017 Jan
12;376(2):125-135. doi: 10.1056/NEJMoa1607427. PubMed PMID: 28076709.
26. Yue Y, Osipov A, Fraass B, Sandler H, Zhang X, Nissen N, Hendifar A, Tuli R. Identifying
prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images
for pancreatic cancer patients. J Gastrointest Oncol. 2017 Feb;8(1):127-138. doi:
10.21037/jgo.2016.12.04. PubMed PMID: 28280617.
27. Hendifar AE, Davies L, Tuli R. Private funding for pancreatic cancer research: more than a
chip shot. Gastroenterology. 2017 Apr;152(5):918-921.e2. doi: 10.1053/j.gastro.2017.02.034.
Epub 2017 Mar 1. PubMed PMID: 28259790.
28. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR,
Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS,
Herrmann K. Most of the intended management changes after (68)Ga-DOTATATE PET/CT
are implemented. J Nucl Med. 2017 Nov;58(11):1793-1796. doi: 10.2967/jnumed.117.192450.
Epub 2017 May 4. PubMed PMID: 28473600.
Andrew E. Hendifar, MD 25
29. Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, Chung JH, Greenbowe J, Ross JS,
Nikiforova MN, Zeh HJ, Sarkaria IS, Dasyam A, Bahary N. Identification of targetable ALK
rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017
May;15(5):555-562. PubMed PMID: 28476735.
30. Osipov A, Nissen N, Rutgers J, Dhall D, Naziri J, Chopra S, Li Q, Hendifar AE, Tuli R.
Redefining the positive margin in pancreatic cancer: impact on patterns of failure, long-term
survival and adjuvant therapy. Ann Surg Oncol. 2017 Nov;24(12):3674-3682. doi:
10.1245/s10434-017-6076-z. Epub 2017 Sep 5. PubMed PMID: 28871564.
31. Manguso N, Johnson J, Harit A, Nissen N, Mirocha J, Hendifar A, Amersi F. Prognostic
factors associated with outcomes in small bowel neuroendocrine tumors. Am Surg. 2017 Oct
1;83(10):1174-1178. PubMed PMID: 29391119.
32. Gangi A, Siegel E, Barmparas G, Lo S, Jamil LH, Hendifar A, Nissen NN, Wolin EM, Amersi
F. Multifocality in small bowel neuroendocrine tumors. J Gastrointest Surg. 2017 Nov 8. doi:
10.1007/s11605-017-3586-8. [Epub ahead of print] PubMed PMID: 29119527.
33. Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R,
Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E,
Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC. Phase II Study of BEZ235
versus everolimus in patients with mammalian target of rapamycin inhibitor-naïve advanced
pancreatic neuroendocrine tumors. Oncologist. 2017 Dec 14. pii: theoncologist.2017-0144. doi:
10.1634/theoncologist.2017-0144. [Epub ahead of print] PubMed PMID: 29242283.
34. Yang G, Dhall D, Yu R, Tuli R, Amersi FF, Friedman ML, Nissen NN, Hendifar AE. The
clinicopathological aspects of primary presacral neuroendocrine neoplasms: one center
experience. Pancreas. 2018 Jan;47(1):122-129. doi:10.1097/MPA.0000000000000954.
PubMed PMID: 29215535.
35. Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS,
Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa
S, Pu J, Aldrich C, Hendifar AE. HALO 202: Randomized phase II study of PEGPH20 plus
nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated,
metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018 Feb 1;36(4):359-366. doi:
10.1200/JCO.2017.74.9564. Epub 2017 Dec 12. PubMed PMID: 29232172.
36. Manguso N, Gangi A, Johnson J, Harit A, Nissen N, Jamil L, Lo S, Wachsman A, Hendifar A,
Amersi F. The role of pre-operative imaging and double balloon enteroscopy in the surgical
management of small bowel neuroendocrine tumors: Is it necessary? J Surg Oncol. 2018
Feb;117(2):207-212. doi: 10.1002/jso.24825. Epub 2017 Sep 20. PubMed PMID: 28940412.
37. Hendifar AE, Chang JI, Huang BZ, Tuli R, Wu BU. Cachexia, and not obesity, prior to
pancreatic cancer diagnosis worsens survival and is negated by chemotherapy. J Gastrointest
Oncol. 2018 Feb;9(1):17-23. doi: 10.21037/jgo.2017.11.10. PubMed PMID: 29564167;
PubMed Central PMCID: PMC5848037.
Andrew E. Hendifar, MD 26
38. Marchevsky AM, Hendifar A, Walts AE. The use of Ki-67 labeling index to grade pulmonary
well-differentiated neuroendocrine neoplasms: current best evidence. Mod Pathol. 2018 May
25. doi: 10.1038/s41379-018-0076-9. [Epub ahead of print] PubMed PMID: 29802361.
39. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E;
NETTER-1 Study Group. Health-related quality of life in patients with progressive midgut
neuroendocrine tumors treated with (177)Lu-Dotatate in the phase III NETTER-1 trial. J Clin
Oncol. 2018 Jun 7:JCO2018785865. doi: 10.1200/JCO.2018.78.5865. [Epub ahead of print]
PubMed PMID: 29878866.
40. Siref A, Balzer B, Hendifar A. Primary visceral merkel cell carcinoma: a case report and
review of the literature. Am J Dermatopathol. 2018 Jun 7. doi:
10.1097/DAD.0000000000001194. [Epub ahead of print] PubMed PMID: 29894357.
41. Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi
VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin
EF. Molecular profiling of pancreatic cancer patients: initial results from the Know Your
Tumor Initiative. Clin Cancer Res. 2018 Jun 28. pii: clincanres.0531.2018. doi:
10.1158/1078-0432.CCR-18-0531. [Epub ahead of print] PubMed PMID: 29954777.
42. Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK,
Biankin AV, Giordano H, Vonderheide RH, Domchek SM. Rucaparib monotherapy in patients
with pancreatic cancer and a known deleterious BRCA mutation. JCO Precis Oncol.
2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16. PubMed PMID: 30051098.
43. Larson BK, Tuli R, Jamil LH, Lo SK, Deng N, Hendifar AE. Utility of endoscopic
ultrasound-guided biopsy for next-generation sequencing of pancreatic exocrine malignancies.
Pancreas. 2018 Jul 19. doi: 10.1097/MPA.0000000000001117. [Epub ahead of print] PubMed
PMID: 30028448.
44. Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, Figlin RA, Meinert CL,
Piantadosi S, Shinde AM. Wearable activity monitors to assess performance status and predict
clinical outcomes in advanced cancer patients. npj Digital Medicine (2018) 1:27;
doi:10.1038/s41746-018-0032-6.
45. Ng K, Hendifar A, Starodub A, Chaves J, Yang Y, Koh B, Barbie D, Hahn WC, Fuchs CS.
Phase 1 dose-escalation study of momelotinib, a Janus kinase ½ inhibitor, combined with
gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic
ductal adenocarcinoma. Invest New Drugs. 2018 Jul 30. doi: 10.1007/s10637-018-0650-5.
[Epub ahead of print] PubMed PMID: 30105668.
Andrew E. Hendifar, MD 27
46. Hendifar AE, Dhall D, Strosberg JR. The evolving treatment algorithm for advanced
neuroendocrine neoplasms: diversity and commonalities across tumor types. Oncologist. 2018
Aug 13. pii: theoncologist.2018-0187. doi: 10.1634/theoncologist.2018-0187. [Epub ahead of
print] PubMed PMID: 30104288.
47. Hendifar AE, Delpassand ES, Kittleson MM, Tuli R. Cardiac toxicity in a patient receiving
peptide receptor radionuclide therapy. Pancreas. 2018 Sep;47(8):e55-e56. doi:
10.1097/MPA.0000000000001101. PubMed PMID: 30113434.
B. Research Papers – Peer Reviewed (In Press)
None
C. Research Papers – Peer Reviewed (Submitted)
None
Research Papers (Non-Peer-Reviewed)
D. Research Papers – Non-Peer Reviewed
None
E. Research Papers – Non-Peer Reviewed (In Press)
None
F. Research Papers – Non-Peer Reviewed (Submitted)
None
CHAPTERS
1. Sandy Liu, Andrew Hendifar, Edward Wolin. Novel Medical Treatments: Management of
Pancreatic Neuroendocrine Tumors. Springer. 2013.
2. Carlyn C Tan, Robert A Figlin, Andrew E Hendifar. The Evolving Role of Mammalian
Target of Rapamycin (mTOR) Inhibitors in Renal Cell Carcinoma. mTOR Inhibition for
Cancer Therapy: Past, Present and Future. Springer. 2014:47.
3. Andrew E Hendifar, Sandy Liu, Edward Wolin. The Role of mTOR inhibitors in
Neuroendocrine Tumors. mTOR Inhibition for Cancer Therapy: Past, Present and Future.
Springer. 2014:93.
4. Osipov A, Tuli R, Hendifar A. Locally Advanced Pancreatic Cancer. Hematology-Oncology
Board Review Manual. 2017 May/June;12(3):14-28.
Andrew E. Hendifar, MD 28
LETTERS TO THE EDITOR
None
REVIEWS
1. Hendifar AE, Ahlmann E, Allison DC, Hu J, Menendez L, Chawla SP. Moving beyond
response criteria: new measures of success in the treatment of sarcomas. Curr Treat Options
Oncol. 2012 Sep;13(3):299-305. doi: 10.1007/s11864-012-0197-1. Review. PubMed PMID:
22644834.
2. Reznik R, Hendifar AE, Tuli R. Genetic determinants and potential therapeutic targets for
pancreatic adenocarcinoma. Front Physiol. 2014 Mar 3;5:87. doi: 10.3389/fphys.2014.00087.
eCollection 2014. Review. PubMed PMID: 24624093.
3. Tan CR, Yaffee PM, Jamil LH, Lo SK, Nissen N, Pandol SJ, Tuli R, Hendifar AE. Pancreatic
cancer cachexia: a review of mechanisms and therapeutics. Front Physiol. 2014 Mar 3;5:88.
doi: 10.3389/fphys.2014.00088. eCollection 2014. Review. PubMed PMID: 24624094.
4. Hendifar A, Tan CR, Annamalai A, Tuli R. Biomarker-driven EGFR therapy improves
outcomes in patients with metastatic colorectal cancer. Expert Rev Anticancer Ther. 2014
Sep;14(9):1051-61. doi: 10.1586/14737140.2014.922881. Epub 2014 Jun 5. Review. PubMed
PMID: 24898788.
5. Yaffee P, Osipov A, Tan C, Tuli R, Hendifar A. Review of systemic therapies for locally
advanced and metastatic rectal cancer. J Gastrointest Oncol. 2015 Apr;6(2):185-200. doi:
10.3978/j.issn.2078-6891.2014.112. Review. PubMed PMID: 25830038.
6. Iriana S, Ahmed S, Gong J, Annamalai AA, Tuli R, Hendifar AE. Targeting mTOR in
Pancreatic Ductal Adenocarcinoma. Front Oncol. 2016 Apr 25;6:99. doi:
10.3389/fonc.2016.00099. eCollection 2016. Review. PubMed PMID: 27200288.
7. Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current
challenges and advances in the diagnosis and management of well-differentiated disease. J
Thorac Oncol. 2017 Mar;12(3):425-436. doi: 10.1016/j.jtho.2016.11.2222. Epub 2016 Nov 24.
Review. PubMed PMID: 27890494.
8. Hendifar A, Bullock A. Breaking the barrier—PEGylated recombinant human hyaluronidase
(PEGPH20)—a new therapeutic approach to the treatment of pancreatic ductal
adenocarcinoma. Oncol Hematol. Review, 2017;13(2):107–11.
9. Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R,
Meinert CL, Piantadosi S. Wearable activity monitors in oncology trials: Current use of an
emerging technology. Contemp Clin Trials. 2017 Nov 9;64:13-21. doi:
10.1016/j.cct.2017.11.002. [Epub ahead of print] Review. PubMed PMID: 29129704.
10. Gong J, Wu D, Chuang J, Tuli R, Simard J, Hendifar A. Moving beyond conventional clinical
trial end points in treatment-refractory metastatic colorectal cancer: a composite quality-of-life
and symptom control end point. Clin Ther. 2017 Oct 24. pii: S0149-2918(17)30999-2. doi:
10.1016/j.clinthera.2017.09.015. [Epub ahead of print] Review. PubMed PMID: 29079389.
Andrew E. Hendifar, MD 29
11. Gong J, Yan J, Forscher C, Hendifar A. Aldoxorubicin: a tumor-targeted doxorubicin
conjugate for relapsed or refractory soft tissue sarcomas. Drug Des Devel Ther. 2018 Apr
6;12:777-786. doi: 10.2147/DDDT.S140638. eCollection 2018. Review. PubMed PMID:
29670334; PubMed Central PMCID: PMC5896668.
12. Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1
blockade: the clinical development of an evolving anticancer combination. J Immunother
Cancer. 2018 Jun 4;6(1):46. doi: 10.1186/s40425-018-0361-7. Review. PubMed PMID:
29866197.
13. Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Combination
systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming
resistance to single-agent checkpoint blockade. Clin Transl Med. 2018 Oct 8;7(1):32. doi:
10.1186/s40169-018-0210-9. Review. PubMed PMID: 30294755; PubMed Central PMCID:
PMC6174117.
EDITORIALS
None
PAPERS IN PREPARATION (RESEARCH COMPLETED)
None
ABSTRACTS
1. Hendifar, Kortes, Blumenthal. Varying mechanisms of influenza hemaglutinin–mediated
conformational change. National Institutes of Health: Poster Day, August 1996. Bethesda,
MD.
2. Hendifar, Kortes, Blumenthal. Conformational changes and fusion activity mediated by
influenza hemaglutinin. National Institutes of Health: Poster Day, August 1997. Bethesda,
MD.
3. Hendifar, Fisher, DeSalvo. Warning: exposure to violence may be hazardous to your health.
2003 Society of General Internal Medicine 26th Annual Meeting. Vancouver, BC, Canada.
4. Hendifar, Zhang, Yang, Igbal, Lenz. Polymorphisms of transforming growth factor-beta 1
and recurrence in stage II and III colon cancer. 2005 American Society of Clinical Oncology
(ASCO) Annual Meeting, May 13-17. Orlando, FL.
5. Yeramian, Hendifar, Brynes, Johnson. Hemophagocytic lymphohistiocytosis: a fatal
presentation of HIV and fever of unknown origin (FUO). 2005 American College Physicians
National Conference. Philadelphia, PA.
Andrew E. Hendifar, MD 30
6. G Lurje, AM Schultheis, AE Hendifar, S Ashouri, W Zhang, MA Gordon, F Nagashima, HM
Chang, D Yang, HJ Lenz. VEGF and VEGF receptor-2 (VEGFR2) gene polymorphisms
predict tumor recurrence in stage II and III colon cancer. 2007 ASCO Annual Meeting, June
1-5. Chicago, IL.
7. G Lurje, W Zhang, D Yang, H Husain, AE Hendifar, Ashouri, A Pohl, Y Ning, S Iqbal, A
El-Khoueiry, HJ Lenz. Polymorphisms in interleukin-1 (IL-1B) and IL-1 receptor antagonist
(IL-1Ra) predict tumor recurrence in stage II colon cancer. 2008 Gastrointestinal Cancers
Symposium, January 25-27. Orlando, FL.
8. AE Hendifar, G Lurje, F Lenz, A Pohl, PC Manegold, K Togawa, H Husain, HJ Lenz, D Yang.
Sex, age, and ethnicity are associated with survival in metastatic colorectal cancer. 2008
ASCO Annual Meeting, May 30-June 3. Chicago, IL. J Clin Oncol. 2008 May 20;26 (15
suppl):4015-4015. (PD)
9. H Husain, G Lurje, D Yang, W Zhang, AE Hendifar, S Ahouri, A Pohl, PC Manegold, S Iqbal,
A El-Khoueiry, H Lenz. Ethnicity is associated with recurrence in patients with resected
gastric cancer. 2008 ASCO Annual Meeting, May 30-June 3. Chicago, IL. (PP)
10. AE Hendifar, D Yang, S Iqbal, H Lenz, A El-Khoueiry. Gender Disparities in hepatocellular
cancer survival. 2009 ASCO Annual Meeting, May 29-June 2. Orlando, FL.
11. J Kim, A Hendifar, D Cao, A Jeng, R Haile. Low rate of screening and surveillance
colonoscopies is associated with advanced colorectal cancer in an urban safety-net hospital.
2009 AGA Institute Clinical Research in Colon Cancer, September 17-19. Chicago, IL.
12. S Lieskovan, A Hendifar, S Ahmed, T Rawi, B Chaudry. A case of warm-antibody
autoimmune hemolytic anemia without spherocytosis. 2009 ACP Regional Conference. Los
Angeles, CA.
13. A Chen, C Lazaro, R Gupta, R Jain, A Hendifar, V Chua, S Chawla. A phase II study of low
dose gemzar, taxotere and adriamycin (TAG) regimen in patients with metastatic soft tissue
sarcomas and failure to prior chemotherapy. 2010 CTOS Annual Meeting, November 11-13.
Paris, France.
14. SP Chawla, CB Lazaro, A Hendifar, RR Gupta, R Rana, R Nadadur, PRG, VS Chua. A phase
II study of VEGF-AS veglin with pemetrexed and cisplatin, CAV regimen, in the treatment of
patients with malignant mesothelioma. 2010 Chicago Multidisciplinary Symposium in
Thoracic Oncology, December 9-11. Chicago, IL. J Thorac Oncol. 2010 Dec;5(12):S529-S529
(suppl 7; abstract 155). (PP)
15. Andrew Hendifar, Shelly Chawla, Vicky Chua, Lita Fernandez, Bartosz Chiemelowski,
James Hu, and Sant Chawla. 14 day continuous infusion high-dose ifosfamide in adolescent
and adult sarcoma patients. 2011 Combined Meeting of the Connective Tissue Oncology
Society and the Musculoskeletal Tumor Society, October 26-29. Chicago, IL. (PP #77)
Andrew E. Hendifar, MD 31
16. Andrew E. Hendifar, SP Chawla, D Quon, VS Chua, L Fernandez, S Nagre, M Okunnu, B
Chmielowski, AS. Singh, S Akmaev, D Chatman, J McCook, Shen Luan, Rangaprasad
Sarangarajan, Paul Y. Song, Niven R Narain. Phase I study of BPM 31510 in advanced solid
tumors: Updated analysis of a novel treatment with promising activity. 2012 ASCO Annual
Meeting, June1-5. Chicago, IL. J Clin Oncol 30, 2012 (suppl; abstr 3015).
17. SP Chawla, V Chua, AE Hendifar, D Quon, S Nagre, KN Ganjoo, K Sankhala, S Wieland, D
Levitt. Phase Ib/II study of INNO-206 (EMCH-doxorubicin) in patients with soft tissue
sarcoma. 2012 ASCO Annual Meeting, June1-5. Chicago, IL. J Clin Oncol 30, 2012 (suppl;
abstr 10036).
18. SP Chawla, VS Chua, A Hendifar, D Quon, S Negre, KN Ganjoo, K Sankhala, Y Lavinski, S
Wieland, D Levitt. INNO-206 is an active drug for+ relapsed advanced soft tissue sarcoma.
2012 ESMO Congress, September 28-October 2. Vienna, Austria. (1483PD)
19. Kristen N Ganjoo, Lee Cranmer, Brian Van Tine, Andrew Hendifar, Esther D Chu, Stew
Kroll, Sant P Chawla. Th-302 maintenance following Th-302 plus doxorubicin induction: the
results of a phase 2 study of TH-302 in combination with doxorubicin in soft tissue sarcoma.
2012 Connective Tissue Oncology Society Annual Meeting, November 14-17. Prague, Czech
Republic.
20. Sant Chawla, Victoria Chua, Andrew Hendifar et al. Aldoxorubin is an active drug for the
treatment of soft tissue sarcoma. 2012 Connective Tissue Oncology Society Annual Meeting,
November 14-17. Prague, Czech Republic.
21. Sant P Chawla, Vivek Narasimhan, Andrew E Hendifar et al. Low dose gemcitabine,
doxorubicin, and docetaxel combination in patients with advanced, unresectable, and/or
metastatic sarcoma who had failed prior chemotherapy, an updated analysis. 2012 Connective
Tissue Oncology Society Annual Meeting, November 14-17. Prague, Czech Republic.
22. Sant P Chawla, Harsha Rajashekharaiah, Andrew E Hendifar et al; Continuous infusion of
high dose ifosfamide in adolescents and adults with soft tissue sarcoma. 2012 Connective
Tissue Oncology Society Annual Meeting, November 14-17. Prague, Czech Republic.
23. Hendifar, A. Results of the randomized phase III trial of trabectedin (T) versus
doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients (pts) with
translocation-related sarcoma (TRS). 2013 ASCO Annual Meeting, May 31-June 4. Chicago,
IL. J Clin Oncol 31, 2013 (suppl; abstr 10517). (PD)
24. Alexandra Gangi, Vijay G. Menon, Marwan Sheckley, Richard Tuli, Andrew Eugene
Hendifar, Ashley Wachsman, Nicholas N. Nissen. Recurrence of pancreatic ductal
adenocarcinoma after pancreaticoduodenectomy: Is there a role for locoregional treatment?
2014 Gastrointestinal Cancers Symposium, January 16-18. San Francisco, CA. J Clin Oncol
32, 2014 (suppl 3; abstr 329). (GPS)
Andrew E. Hendifar, MD 32
25. Richard Tuli, Benedick Fraass, Wensha Yang, Howard Mark Sandler, Andrew Hendifar,
Nicholas N. Nissen, Yong Yue. Pretreatment [18F] FDG-PET texture analysis to predict local
response of pancreatic cancer to radiotherapy. 2014 Gastrointestinal Cancers Symposium,
January 16-18. San Francisco, CA. J Clin Oncol 32, 2014 (suppl 3; abstr 375) (GPS)
26. Richard Tuli, Wensha Yang, Mourad Tighiouart, Yong Yue, Benedick Fraass, Howard Mark
Sandler, Andrew Eugene Hendifar, Nicholas N. Nissen. 18F-FDG PET as a predictor of
resectability and clinical outcomes in locally advanced pancreatic cancer patients treated with
radiotherapy. 2014 Gastrointestinal Cancers Symposium, January 16-18. San Francisco, CA. J
Clin Oncol 32, 2014 (suppl 3; abstr 378). (GPS)
27. Susan M Domchek, Robert McWilliams, Andrew Hendifar, Rachna T Shroff, Lawrence
Leichman, Ron Epelbaum, Ravit Geva, George Kim, Steven R Alberts, Robert A Wolff,
Andrew Allen, Heidi Giordano, Mitch Raponi, Jeff Isaacson, Lindsey Rolfe, Andrew Biankin,
Robert H Vonderheide. A phase 2, open-label study of the PARP inhibitor rucaparib in patients
with pancreatic cancer and a known deleterious BRCA mutation. 2014 AACR Pancreatic
Cancer: Innovations in Research and Treatment, May 18-21. New Orleans, LA. Cancer Res.
2015 June 30;75(13 Supplement):B102-B102.
28. Andrew Eugene Hendifar, Carlyn Rose Co Tan, Patrick Yaffee, Arsen Osipov, Richard Tuli,
Christie Y Jeon. Evaluating outcomes of pancreatic cancer patients with cacehxia. 2014 ASCO
Annual Meeting, May 30-June 3. Chicago, IL. J Clin Oncol 32, 2014 (suppl; abstr e15208).
29. Carlyn Rose Co Tan, Rhonda Aizenberg, Lynne Davies, Lynn Matrisian, Xiao Zhang, Richard
Tuli, Andrew Eugene Hendifar. The shifting landscape of pancreatic cancer research funding.
2014 ASCO Annual Meeting, May 30-June 3. Chicago, IL. J Clin Oncol 32, 2014 (suppl; abstr
e17545).
30. Susan M Domchek, Robert R McWilliams, Andrew Eugene Hendifar, Rachna T Shroff,
Lawrence P Leichman, Ron Epelbaum, Ravit Geva, George P Kim, Steven R Alberts, Robert
A Wolff, Andrew R Allen, Heidi Giordano, Mitch Raponi, Jeffrey D Isaacson, Lindsey Rolfe,
Andrew Biankin, Robert H Vonderheide. A phase 2, open-label study of rucaparib in patients
with pancreatic cancer and a known deleterious BRCA mutation. 2014 ASCO Annual Meeting,
May 30-June 3. Chicago, IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4161).
31. Andrew E Hendifar, Sue Swain, Loni Lee, Jasleen Khanuja, Arsen Osipov, Nick Nissen,
Richard Tuli. A study of rucaparib in patients with pancreatic cancer and a known deleterious
BRCA mutation. 2014 20th Anniversary BRCA Gene Symposium: Advances in Care for the
New Millennium, September 13. Los Angeles, CA.
32. Andrew Hendifar, Nicholas Nissen, David Hoffman, Stephen Miles, Miranda Bryant,
Mourad Tighiouart, Andre Rogatko, Simon Lo, Ashley Wachsman, Arsen Osipov, Richard
Tuli. Phase I study of veliparib with gemcitabine and radiation therapy in patients with locally
advanced unresectable pancreatic cancer. 2014 20th Anniversary BRCA Gene Symposium:
Advances in Care for the New Millennium, September 13. Los Angeles, CA.
Andrew E. Hendifar, MD 33
33. A Hendifar, Jasleen Khanuja, Gillian Gresham, Arsen Osipov, Carlyn-Rose Tan, Richard Tuli.
Treatment and underlying mechanisms of pancreatic cancer cachexia. 2014 2nd Cancer
Cachexia Conference: Evolving Mechanisms and Therapies, September 26-28. Montreal,
Canada.
34. Andrew Hendifar, Arsen Osipov, Jason Naziri, Wensha Yang, Nicholas Nissen, Richard Tuli.
Body Mass Index and Outcomes in a Cohort of Resected Pancreatic Cancer Patients. 2014
American Pancreatic Association & Japan Pancreas Society Annual Meeting, November 5-8.
Waimea, Big Island, HI.
35. Jasleen Khanuja, Gillian Gresham, Arsen Osipov, Richard Tuli, Andrew Eugene Hendifar.
Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study). 2015
Gastrointestinal Cancers Symposium, January 15-17. San Francisco, CA. J Clin Oncol 33,
2015 (suppl 3; abstr TPS491).
36. Arsen Osipov, Jason Naziri, Andrew Eugene Hendifar, Deepti Dhall, Joanne K Rutgers,
Shefali Chopra, Quanlin Li, Alagappan Annamalai, Mourad Tighiouart, Nicholas N Nissen,
Richard Tuli. Impact of margin status and lymphadenectomy on clinical outcomes in resected
pancreatic cancer: implications for adjuvant radiotherapy. 2015 Gastrointestinal Cancers
Symposium, January 15-17. San Francisco, CA. J Clin Oncol 33, 2015 (suppl 3; abstr 429).
37. S Libutti, R Garcia-Carbonero, EM Wolin, A Custodio, JC Yao AE Hendifar, R Tavorath, N
Mukherjee, F Herbst, J Sulovski, R Salazar. CBEZ235Z2401: Randomized phase II study of
BEZ235 or everolimus (EVE) in patients with advanced pancreatic neuroendocrine tumors
(pNET). ENETS, 2015 12th Annual Conference for the Diagnosis and Treatment of
Neuroendocrine Tumor Disease, March 11-13. Barcelona, Spain. Neuroendocrinology. 2015
102:131-131
38. Andrew Eugene Hendifar, Xiao Zhang, Rhonda Aizenberg, Mila McCurrach, Pat Morin,
Richard Tuli, Lynn Matrisian, Lynne Davies. A quantitative analysis of funding for pancreatic
cancer research. 2015 ASCO Annual Meeting, May 29-June 2. Chicago, IL. J Clin Oncol 33,
2015 (suppl; abstr 4126).
39. Andrew Eugene Hendifar, Neal S Chawla, Kamalesh Kumar Sankhala, Xiao Zhang, Doris V.
Quon, Victoria S Chua, Lita Fernandez, William E. Mendanha, Sant P. Chawla. Phase 2 study
of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or
metastatic sarcoma who have failed prior therapies. 2015 ASCO Annual Meeting, May
29-June 2. Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr 10573).
40. Arsen Osipov, Jasleen Khanuja, Quanlin Li, Jason Naziri, Andrew Eugene Hendifar,
Richard Tuli. The influence of body mass index and albumin on perioperative morbidity and
clinical outcomes in resected pancreatic adenocarcinoma. 2015 ASCO Annual Meeting, May
29-June 2. Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr e15210).
Andrew E. Hendifar, MD 34
41. Sunil R. Hingorani, William Proctor Harris, Andrew Eugene Hendifar, Andrea J. Bullock,
Xionghua W. Wu, Ya Huang, Ping Jiang. High response rate and PFS with PEGPH20 added to
nab-paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients with
high-HA tumors: interim results of a randomized phase II study. 2015 ASCO Annual Meeting,
May 29-June 2. Chicago, IL. J Clin Oncol 33, 2015 (suppl; abstr 4006).
42. A. Hendifar, S. Hingorani, W. Harris, T. Seery, D. Sigal, W. Wu, S. Dychter, P. Jiang. High
response rate and PFS with PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV
previously untreated pancreatic cancer patients with high-HA tumors: interim results of a
randomized phase 2 study. 2015 ESMO World Congress on Gastrointestinal Cancer, July 1-4.
Barcelona, Spain. Ann Oncol. 2015 June;26(suppl_4):iv117. (LBA 02)
43. J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, RP Baum, E Mittra, T
Hobday, A Hendifar, K Oberg, M Lopera Sierra, P Ruszniewski, D Kwekkeboom..
177-Lu-Dotatate significantly improves progression-free survival in patients with midgut
neuroendocrine tumours: results of the phase III NETTER-1 trial. 2015 European Cancer
Congress, September 25-29. Vienna, Austria. (LBA 6) (Presidential Session)
44. S Hingorani, W Harris, A Hendifar, A Bullock, X Wu, Y Huang, P Jiang, D Von Hoff. High
response rate and progression free survival with PEGylated recombinant human hyaluronidase
added to Nab-Paclitaxel/ Gemcitabine in stage IV previously untreated pancreatic cancer
patients with high-HA tumors: interim results of a randomized phase 2 study. 2015 European
Cancer Congress, September 25-29. Vienna, Austria. Eur J Cancer. 2015
September;51(3):S439–S440. (suppl; abstr 2321) (PS)
45. A. Baecker, S.J. Pandol, A. Hendifar, N. Nissen, B. Wu, C.Y. Jeon. Applying healthcare
utilization data to predict pancreatic cancer. 2015 American Pancreatic Association Annual
Meeting, November 4-7. San Diego, CA. Pancreas. 2015 November;44(8):1358–1430.
46. Anitra Engebretson, Jonathan Robert Brody, Lola Rahib, Lynn Matrisian, Andrew Eugene
Hendifar, William Arthur Hoos, Sameh Mikhail, Vincent M Chung, Vincent J Picozzi, Craig
Heartwell, Kimberly Mason, Katelyn Varieur, Subha Madhavan, Emanuel Petricoin, Michael
J Pishvaian. The Know Your Tumor (KYT) initiative: a national program of multi-omic
molecular profiling (MoP) for patients (Pts) with pancreatic cancer (PDA). 2016
Gastrointestinal Cancers Symposium, January 21-23. San Francisco, CA. J Clin Oncol 34,
2016 (suppl 4S; abstr 279). (PS)
47. Michael J Pishvaian, Lynn Matrisian, Andrew Eugene Hendifar, Anitra Engebretson, Lola
Rahib, William Arthur Hoos, Sameh Mikhail, Vincent M Chung, Vincent J Picozzi, Craig
Heartwell, Kimberly Mason, Katelyn Varieur, Subha Madhavan, Emanuel Petricoin, Jonathan
Robert Brody. Preliminary observations of blood-based (BB) molecular testing in a subset of
patients with pancreatic cancer (PDA) participating in the Know Your Tumor (KYT) initiative.
2016 Gastrointestinal Cancers Symposium, January 21-23. San Francisco, CA. J Clin Oncol
34, 2016 (suppl 4S; abstr 268). (PS)
Andrew E. Hendifar, MD 35
48. Sanjay Goel, Lucjan Wyrwicz, Minsig Choi, Andrew L Coveler, Antonio Ucar, Alexander
Ward Brown, Tomasz Sarosiek, Lucas Wong, Michael Stecher, George A Fisher, Andrew
Eugene Hendifar. Phase III double-blinded, placebo-controlled study of MABp1 for
improving survival in metastatic colorectal cancer. 2016 Gastrointestinal Cancers Symposium,
January 21-23. San Francisco, CA. J Clin Oncol 34, 2016 (suppl 4S; abstr TPS784).
49. Richard Tuli, Nicholas N Nissen, Alagappan Annamalai, David MJ Hoffman, Miranda Bryant,
Mourad Tighiouart, Andre Rogatko, Sepehr Rokhsar, Kevin S Scher, Laith Jamil, Simon Lo,
Andrew Eugene Hendifar. Phase I study of veliparib with gemcitabine and radiation therapy
in patients with borderline resectable and locally advanced unresectable pancreatic cancer.
2016 Gastrointestinal Cancers Symposium, January 21-23. San Francisco, CA. J Clin Oncol
34, 2016 (suppl 4S; abstr TPS487).
50. Jonathan R Strosberg, Edward M Wolin, Beth Chasen, Matthew H Kulke, David L Bushnell,
Martyn E Caplin, Richard P Baum, Pamela L Kunz, Timothy J Hobday, Andrew Eugene
Hendifar, Kjell E Oberg, Maribel Lopera Sierra, Dik J Kwekkeboom, Philippe B Ruszniewski,
Eric Krenning. NETTER-1 phase III: Progression-free survival, radiographic response, and
preliminary overall survival results in patients with midgut neuroendocrine tumors treated with
177-Lu-Dotatate. 2016 Gastrointestinal Cancers Symposium, January 21-23. San Francisco,
CA. J Clin Oncol 34, 2016 (suppl 4S; abstr 194). (PS)
51. Michael J Pishvaian, Jonathan Robert Brody, Lynn Matrisian, Andrew Eugene Hendifar,
Anitra Engebretson, William Arthur Hoos, Sameh Mikhail, Vincent M Chung, Vincent J
Picozzi, Corinne Ramos, Craig Heartwell, Kimberly Mason, Katelyn Varieur, Lola Rahib,
Emanuel Petricoin, Subha Madhavan. Multi-Omic profiling (MoP) for patients (pts) with
pancreatic cancer (PDA): initial results of the Know Your Tumor (KYT) initiative. 2016
Gastrointestinal Cancers Symposium, January 21-23. San Francisco, CA. J Clin Oncol 34,
2016 (suppl 4S; abstr 282). (PS)
52. Sunil R Hingorani, William Proctor Harris, Tara Elisabeth Seery, Lei Zheng, Darren Sigal,
Andrew Eugene Hendifar, Fadi S Braiteh, Mark Zalupski, Ari David Baron, Nathan Bahary,
Andrea Wang-Gillam, Noelle K LoConte, Gregory M Springett, Paul S Ritch, Aram F Hezel,
Wen Wee Ma, Venu Gopal Bathini, Xionghua W Wu, Ping Jiang, Andrea J Bullock. Interim
results of a randomized phase II study of PEGPH20 added to nab-paclitaxel/gemcitabine in
patients with stage IV previously untreated pancreatic cancer. 2016 Gastrointestinal Cancers
Symposium, January 21-23. San Francisco, CA. J Clin Oncol 34, 2016 (suppl 4S; abstr 439).
(PS)
53. Jeffrey Toll, Arsen Osipov, Jasleen Khanuja, Dana Pan, Rishi Patel, Jenny Zhou, Arvind
Manohar Shinde, Alagappan Annamalai, Andrew Eugene Hendifar, Richard Tuli. DNA
sequencing to identify potentially novel targets for therapy in pancreatic cancer. 2016
Gastrointestinal Cancers Symposium, January 21-23. San Francisco, CA. J Clin Oncol 34,
2016 (suppl 4S; abstr 275). (PS)
Andrew E. Hendifar, MD 36
54. Eve Makoff, Arvind Manohar Shinde, Richard Tuli, Andrew Eugene Hendifar. Panc Support
Project (PSP): evaluating the integration of palliative care into a pancreatic cancer program at a
comprehensive cancer center. 2016 ASCO Quality Care Symposium, February 26-27. Phoenix,
AZ. J Clin Oncol 34, 2016 (suppl 7S; abstr 241). (PS)
55. Arvind Manohar Shinde, Azadeh Dashti, Eve Makoff, Navasard Ovasapians, Andrew Eugene
Hendifar, Richard Tuli, Robert A Figlin. MD and RN ECOG-PS assessments prior to
chemotherapy and concordance rates: a quality initiative at a comprehensive cancer center.
2016 ASCO Quality Care Symposium, February 26-27. Phoenix, AZ. J Clin Oncol 34, 2016
(suppl 7S; abstr 228).
56. Andrea J Bullock, Sunil R Hingorani, Xionghua W Wu, Ping Jiang, Dimitrios Chondros,
Sihem Khelifa, Carrie Aldrich, Jie Pu, Andrew Eugene Hendifar. Final analysis of stage 1
data from a randomized phase II study of PEGPH20 plus nab-Paclitaxel/gemcitabine in stage
IV previously untreated pancreatic cancer patients (pts), utilizing Ventana companion
diagnostic assay. 2016 ASCO Annual Meeting, June 3-7. Chicago, IL. J Clin Oncol 34, 2016
(suppl; abstr 4104). (PS)
57. Jeffrey Toll, Quanlin Li, Arsen Osipov, Jenny Zhou, Rishi Patel, Dana Pan, Jasleen Khanuja,
Miranda Bryant, Richard Tuli, Andrew Eugene Hendifar. Identifying novel genetic
alterations for risk stratification and prognostication in pancreatic cancer. 2016 ASCO Annual
Meeting, June 3-7. Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr e15754).
58. Jonathan R Strosberg, Edward M Wolin, Beth Chasen, Matthew H Kulke, David L Bushnell,
Martyn E Caplin, Richard P Baum, Timothy J Hobday, Andrew Eugene Hendifar, Kjell E
Oberg, Maribel Lopera Sierra, Dik J Kwekkeboom, Philippe B Ruszniewski, Eric Krenning,
Pamela L Kunz. NETTER-1 phase III: efficacy and safety results in patients with midgut
neuroendocrine tumors treated with 177Lu-Dotatate. 2016 ASCO Annual Meeting, June 3-7.
Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4005). (OAS)
59. Arsen Osipov, Joanne K Rutgers, Deepti Dhall, Jason Naziri, Shefali Chopra, Quanlin Li,
Nicholas N Nissen, Richard Tuli, Andrew Eugene Hendifar. Redefining the positive margin
in pancreatic cancer: impact of distance on survival. 2016 ASCO Annual Meeting, June 3-7.
Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4122). (PS)
60. Susan M Domchek, Andrew Eugene Hendifar, Robert R McWilliams, Ravit Geva, Ron
Epelbaum, Andrew Biankin, Robert H Vonderheide, Robert A Wolff, Steven R Alberts, Heidi
Giordano, Sandra Goble, Kevin K Lin, Rachna T Shroff. RUCAPANC: An open-label, phase
2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a
known deleterious germline or somatic BRCA mutation. 2016 ASCO Annual Meeting, June
3-7. Chicago, IL. J Clin Oncol 34, 2016 (suppl; abstr 4110). (PS)
Andrew E. Hendifar, MD 37
61. Arvind Manohar Shinde, Gillian K Gresham, Andrew Eugene Hendifar, Richard Tuli,
Brennan Spiegel, Robert A Figlin. Biosensors to assess performance status in cancer (BioAPS
Study). 2016 ASCO Annual Meeting, June 3-7. Chicago, IL. J Clin Oncol 34, 2016 (suppl;
abstr TPS6631). (PS)
62. S Hingorani, A Bullock, W Harris, W Wu, P Jiang, D Chondros, S Khelifa, C Aldrich, J Pu, A
Hendifar. Final analysis of stage 1 data from a randomized phase 2 study of PEGPH20 plus
nab-Paclitaxel/gemcitabine in stage IV previously untreated pancreatic cancer patients,
utilizing Ventana companion diagnostic assay. 2016 ESMO World Congress on
Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016
June;27(suppl_2):ii103. (PD 006)
63. J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, R Baum, P Kunz, T Hobday,
K Oberg, M Lopera Sierra, D Kwekkeboom, P Ruszniewski, E Krenning, A Hendifar.
NETTER-1 phase III: efficacy and safety results in patients with midgut neuroendocrine
tumors treated with 177Lu-Dotatate. 2016 ESMO World Congress on Gastrointestinal Cancer,
June 29-July 2. Barcelona, Spain. Ann Oncol. 2016 June;27(suppl_2):ii121. (O 009)
64. E Van Cutsem, AE Hendifar, M Reni, WP Harris, M Ducreux, A Bullock, P Corrie, V
Heinemann, T Seery, D Chondros, L Zheng. Global phase 3, randomized, double-blind,
placebo-controlled study evaluating PEGylated recombinant human hyaluronidase PH20
(PEGPH20) plus nab-paclitaxel and gemcitabine in patients with previously untreated,
hyaluronan (HA)-high, stage IV pancreatic ductal adenocarcinoma. 2016 ESMO World
Congress on Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016
Oct.;27(suppl_6):715TiP.
65. J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, R Baum, PL Kunz, T
Hobday, A Hendifar, K Oberg, M Lopera Sierra, D Kwekkeboom, P Ruszniewski, E
Krenning. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with
177Lu-Dotatate: efficacy, safety, QOL results and subgroup analysis. 2016 ESMO World
Congress on Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016
Oct.;27(suppl_6):420PD.
66. Tempero, Margaret; Hingorani Sunil; Zheng, Lei; Reni, Michele; Hendifar, Andrew;
Ducreux, Michel; Bullock, Andrea; Corrie, Pippa; Harris, William; Heinemann, Volker; Seery,
Tara; Wu, Wilson; Chondros, Dimitrios; Van Cutsem, Eric. Global Phase 3, Randomized,
double-blind, placebo-controlled, multicenter study to compare efficacy and safety of
PEGylated recombinant human hyaluronidase (PEGPH20) plus nab-paclitaxel and
gemcitabine vs. placebo plus nab-paclitaxel and gemcitabine. 2016 ESMO World Congress on
Gastrointestinal Cancer, June 29-July 2. Barcelona, Spain. Ann Oncol. 2016
June;27(suppl_2):ii84. (P 288)
Andrew E. Hendifar, MD 38
67. Brent K Larson, Dana Pan, Jasleen Khanuja, Rishi Patel, Jenny Zhou, Arsen Osipov, Maha
Guindi, Thomas Müller, Quanlin Li, Ping Jiang, Richard Tuli, Andrew Eugene Hendifar.
Association of hyaluronan accumulation with clinical-pathologic features in pancreatic ductal
adenocarcinomas. 2017 Gastrointestinal Cancers Symposium, January 19-21. San Francisco,
CA. J Clin Oncol 35, 2017 (suppl 4S; abstract 322). (PS)
68. R Joseph Bender, David Halverson, Kimberly Mason, Linlin Luo, Jonathan Robert Brody,
Lola Rahib, Lynn McCormick Matrisian, Andrew Eugene Hendifar, William Arthur Hoos,
Sameh Mikhail, Vincent M Chung, Vincent J Picozzi, Corinne Ramos, Craig Heartwell,
Katelyn Varieur, Metasebia Aberra, Emanuel Petricoin, Subha Madhavan, Michael J
Pishvaian. Molecular biomarkers as predictors of patient survival in pancreatic
adenocarcinoma (PDA): an analysis of the Know Your Tumor initiative (KYT). 2017
Gastrointestinal Cancers Symposium, January 19-21. San Francisco, CA. J Clin Oncol 35,
2017 (suppl 4S; abstract 278). (PS)
69. Jonathan R Strosberg, Edward M Wolin, Beth Chasen, Matthew H Kulke, David L Bushnell,
Martyn E Caplin, Richard P Baum, Pamela L Kunz, Timothy J Hobday, Andrew Eugene
Hendifar, Kjell E Oberg, Maribel Lopera Sierra, Dik J Kwekkeboom, Philippe B Ruszniewski,
Eric Krenning. Quality-of-life findings in patients with midgut neuroendocrine tumors: results
of the NETTER-1 phase III trial. 2017 Gastrointestinal Cancers Symposium, January 19-21.
San Francisco, CA. J Clin Oncol 35, 2017 (suppl 4S; abstract 348). (PS)
70. Brent K Larson, Nan Deng, Richard Tuli, Andrew Eugene Hendifar. Utility of endoscopic
ultrasound-guided biopsy for genomic analysis of pancreatic exocrine malignancies. 2017
Gastrointestinal Cancers Symposium, January 19-21. San Francisco, CA. J Clin Oncol 35,
2017 (suppl 4S; abstract 423). (PS)
71. Rishi Patel, R Joseph Bender, Quanlin Li, Dana Pan, Richard Tuli, Michael J. Pishvaian,
Andrew Eugene Hendifar. Multi-omic molecular profiling of pancreatic neuroendocrine
tumors. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl;
abstr e 15685).
72. Gillian K. Gresham, Elad Neeman, Andrew Eugene Hendifar, Quanlin Li, Richard Tuli, Bj
Rimel, Christine S. Walsh, Brennan Spiegel, Robert A. Figlin, Steven Piantadosi, Arvind
Manohar Shinde. Assessing performance status and clinical outcomes with wearable activity
monitors. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl;
abstr 6571). (PS Board #393)
73. Andrew Eugene Hendifar, Harris S Soifer, Mason Israel, Catherine A. Schnabel. Molecular
classification of neuroendocrine tumors: Clinical experience with the 92-gene assay
in >24,000 cases. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017
(suppl; abstr e 15700).
Andrew E. Hendifar, MD 39
74. Arsen Osipov, Quanlin Li, Shant Thomassian, Lakshmanan Annamalai, Jennifer Holmes
Yearley, Joanne K Rutgers, Andrew Eugene Hendifar, Richard Tuli. Impact of
chemoradiotherapy on PD1/PDL1 expression and clinical outcomes in gastroesophageal
cancers. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl;
abstr 4031). (PS Board #23)
75. Nicholas Manguso, Attiya Harit, Nicholas N. Nissen, James Mirocha, Andrew Eugene
Hendifar, Farin F. Amersi. Prognostic factors influencing survival in small bowel
neuroendocrine tumors with liver metastasis. 2017 ASCO Annual Meeting, June 2-6. Chicago,
IL. J Clin Oncol 35, 2017 (suppl; abstr e 15688).
76. Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S.
Ritch, Fadi S. Braiteh, Mark Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Carrie
Aldrich, Sihem Khelifa, Xionghua W. Wu, Joaquina Baranda, Ping Jiang, Andrew Eugene
Hendifar. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs
AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).
2017 ASCO Annual Meeting, June 2-6. Chicago, IL. J Clin Oncol 35, 2017 (suppl; abstr
4008).
77. Arvind Manohar Shinde, Gillian K. Gresham, Andrew Eugene Hendifar, Quanlin Li, Brennan
Spiegel, Bj Rimel, Christine S. Walsh, Richard Tuli, Steven Piantadosi, Robert A. Figlin.
Correlating wearable activity monitor data with PROMIS detected distress and physical
functioning in advanced cancer patients. 2017 ASCO Annual Meeting, June 2-6. Chicago, IL.
J Clin Oncol 35, 2017 (suppl; abstr e21689).
78. Sunil Hingorani, Andrea Bullock, Tara Seery, Lei Zheng, Darren Sigal, Paul Ritch, Fadi
Braiteh, Mark Zalupski, Nathan Bahary, William Harris Jie Pu, Carrie Aldrich, Sihem Khelifa,
Wilson Wu, Joaquina Baranda, Ping Jiang, Andrew Hendifar. PEGPH20 improves PFS in
patients with metastatic pancreatic ductal adenocarcinoma: a randomized phase 2 study in
combination with nab-paclitaxel/gemcitabine. 2017 ESMO World Congress on
Gastrointestinal Cancer, June 28-July 1. Barcelona, Spain. Ann Oncol. 2017. (supp, abstract O
003).
79. Andrew Hendifar, Andrea Bullock, Tara Seery, Lei Zheng, Darren Sigal, Paul Ritch, Fadi
Braiteh, Mark Zalupski, Nathan Bahary, William Harris Jie Pu, Fangru Lian, Junming Zhu,
Wilson Wu, Joaquina Baranda, Ping Jiang, Sunil Hingorani. Tumor hyaluronan may predict
benefit from PEGPH20 when added to nab paclitaxel/gemcitabine in patients with previously
untreated metastatic pancreatic ductal adenocarcinoma (mPDA). 2017 ESMO World Congress
on Gastrointestinal Cancer, June 28-July 1. Barcelona, Spain. Ann Oncol 28, 2017. (sup_3,
abstract O-028).
Andrew E. Hendifar, MD 40
80. E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreaux, W Harris, P Corrie, T Seery, D
Chondros, A Bullock. Global phase 3, randomized, double-blind, placebo-controlled study
evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) + nab-paclitaxel
& gemcitabine in patients with previously untreated, hyaluronan-high, stage IV pancreatic
ductal adenocarcinoma. 2017 ESMO World Congress on Gastrointestinal Cancer, June
28-July 1. Barcelona, Spain. Ann Oncol 28, 2017. (sup_3, P-043).
81. I Lapite, M Guan, A Hendifar. Patient Preferences for Quality of Life Domains in Pancreatic
Cancer. 3rd Annual Research Internship Poster Day. Cedars-Sinai Medical Center. Los
Angeles, CA. August 4, 2017.
82. M Guan, I Lapite, BK Larson, D Pan, J Khanuja, R Patel, J Zhou, A Osipov, M Guindi, T
Muller, Q Li, P Jiang, R Tuli, A Hendifar. Association Between Hyaluronic Acid Expression
and Clinical/Pathological Variables in Pancreatic Ductal Adenocarcinoma. 3rd Annual
Research Internship Poster Day. Cedars-Sinai Medical Center. Los Angeles, CA. August 4,
2017.
83. J Strosberg, EM Wolin, B Chasen, MH Kulke, D Bushnell, M Caplin, RP Baum, P Kunz, T
Hobday, A Hendifar, K Öberg, M Lopera Sierra, P Ruszniewski, E Krenning. Improved time
to quality of life deterioration in patients with progressive midgut neuroendocrine tumors
treated with 177Lu-Dotatate: the NETTER-1 phase III trial. 2017 ESMO Congress, September
8-12. Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (PD #438)
84. A Hendifar, A Bullock, . Seery, L Zheng, D Sigal, PS Ritch, FS Braiteh, M Zalupski, N
Bahary, W Harris, J Pu, F Lian, J Zhu, W Wu, D Chondros, P Jiang, SR Hingorani. Tumor
hyaluronan (HA) is a novel biomarker: Results of the randomized phase 2 HALO 202 study of
PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in previously untreated,
metastaticpancreatic ductal adenocarcinoma (mPDA). 2017 ESMO Congress, September 8-12.
Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (P #743)
85. A Bullock, P Vervaet, W Wu, D Chondros, SR Hingorani, A Hendifar. Musculoskeletal
Events (MSEs) with PEGPH20 treatment and management in patients with previously
untreated metastatic pancreatic ductal adenocarcinoma (mPDA). 2017 ESMO Congress,
September 8-12. Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (P #749)
86. SR Hingorani, A Bullock, T Seery, L Zheng, D Sigal, PS Ritch, FS Braiteh, M Zalupski, N
Bahary, W Harris, J Pu, C Aldrich, S Khelifa, W Wu, D Chondros, P Jiang, A Hendifar.
Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in
patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). 2017
ESMO Congress, September 8-12. Madrid, Spain. Ann Oncol 28 (Supplement 5), September
2017. (P #763)
Andrew E. Hendifar, MD 41
87. E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreaux, W Harris, P Corrie, T Seery, D
Chondros, A Bullock. Global phase 3, randomized, double-blind, placebo-controlled study
evaluating PEGylated recombinant human hyaluronidase PH20 (PEGPH20) plus
nab-paclitaxel and gemcitabine in patients with previously untreated, hyaluronan (HA)-high,
stage IV pancreatic ductal adenocarcinoma (PDA). 2017 ESMO Congress, September 8-12.
Madrid, Spain. Ann Oncol 28 (Supplement 5), September 2017. (TiP 774)
88. D-Y Oh, Y-J Bang, E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreux, W Harris, P
Corrie, T Seery, D Chondros, A Bullock, C-P Li. Phase 3, randomized, double-blind,
placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)
+ nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV
pancreatic ductal adenocarcinoma (PDA). ESMO Asia 2017 Congress, November 17-19.
Singapore. Ann Oncol 28 (Supplement 10, abstract #1663), November 2017. (TiP 260)
89. D-Y Oh, Y-J Bang, E Van Cutsem, A Hendifar, M Reni, L Zheng, M Ducreux, W Harris, P
Corrie, T Seery, D Chondros, A Bullock, C-P Li. Phase 3, randomized, double-blind,
placebo-controlled study of PEGylated recombinant human hyaluronidase PH20 (PEGPH20)
+ nab-paclitaxel/gemcitabine in patients with previously untreated, hyaluronan-high, stage IV
pancreatic ductal adenocarcinoma (PDA). 25th International Symposium on Advances in the
Treatment of Digestive Tumors, December 14, 2017. Seville, Spain.
90. John David, Sungjin Kim, Erik Anderson, Arman Torossian, Simon Lo, Nicholas N Nissen,
Andrew Eugene Hendifar, Richard Tuli. Treatment at high-volume facilities and academic
centers in relation to overall survival in patients with locally advanced pancreatic cancer: A
National Cancer Database analysis. 2018 Gastrointestinal Cancers Symposium, January 18-20.
San Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 392). (PS)
91. Eric Anderson, John David, Simon Lo, Nicholas N Nissen, Andrew Eugene Hendifar,
Richard Tuli. Curative intent surgery and associated overall survival variation between elderly
and younger patients in the National Cancer Database. 2018 Gastrointestinal Cancers
Symposium, January 18-20. San Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 373).
(PS)
92. John David, Sungjin Kim, Eric Anderson, Arman Torossian, Simon Lo, Nicholas N Nissen,
Andrew Eugene Hendifar, Richard Tuli. Effect of multiagent chemotherapy and
chemoradiotherapy on rates of resection and survival in patients with locally advanced
pancreatic cancer: a National Cancer Database Analysis. 2018 Gastrointestinal Cancers
Symposium, January 18-20. San Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 391).
(PS)
93. John David, Yong Yue, Kevin Blas, Benedick Fraass, Andrew Eugene Hendifar, Peyman
Kabolizadeh, Richard Tuli. 18F-FDG PET-defined therapy response to predict acute
hematologic toxicity for anal cancer patients treated with chemoradiation. 2018
Gastrointestinal Cancers Symposium, January 18-20. San Francisco, CA. J Clin Oncol 36,
2018 (suppl 4S; abstr 775). (PS)
Andrew E. Hendifar, MD 42
94. Aatur D. Singhi, Joel R Greenbowe, Jon Chung, Andrew Eugene Hendifar, Nathan Bahary,
Alexa Betzig Schrock, Vincent A Miller, Philip J Stephens, Jeffrey S Ross, Siraj Mahamed Ali,
Ben George. Comprehensive genomic profiling to identify recurrent kinase fusions in
pancreatic ductal adenocarcinoma. 2018 Gastrointestinal Cancers Symposium, January 18-20.
San Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 292). (PS)
95. Michelle Guan, R Joseph Bender, Michael J Pishvaian, David Charles Halverson, Richard Tuli,
Samuel Jacob Klempner, Zev A Wainberg, Aatur D Singhi, Emanuel Petricoin, Andrew
Eugene Hendifar. Molecular and clinical characterization of BRAF mutations in pancreatic
ductal adenocarcinomas (PDACs). 2018 Gastrointestinal Cancers Symposium, January 18-20.
San Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 214). (PS)
96. Ben George, Joel R Greenbowe, Andrew Eugene Hendifar, Talia Golan, Milind M Javle,
Anirban Maitra, Nathan Bahary, Alexa Betzig Schrock, Philip J Stephens, Vincent A Miller,
Jeffrey S Ross, Evgeny Yakirevich, Paul S Ritch, James P Thomas, Siraj Mahamed Ali, Aatur
D Singhi. Comprehensive genomic profiling (CGP) in KRAS wild-type (WT) pancreatic ductal
adenocarcinoma (PDAC). 2018 Gastrointestinal Cancers Symposium, January 18-20. San
Francisco, CA. J Clin Oncol 36, 2018 (suppl 4S; abstr 271). (PS)
97. Gagandeep Brar, Edik Blais, R Joseph Bender, Jonathan Brody, Davendra Sohal, Subha
Madhavan, Vincent J Picozzi, Andrew Eugene Hendifar, Vincent M Chung, David
Halverson, Sameh Mikhail, Lynn McCormick Matrisian, Lola Rahib, Emanuel Petricoin,
Michael J Pishvaian. Multiomic molecular comparison of primary versus metastatic pancreatic
tumors. 2018 Gastrointestinal Cancers Symposium, January 18-20. San Francisco, CA. J Clin
Oncol 36, 2018 (suppl 4S; abstr 213). (PS)
98. Richard Tuli, Nicholas N. Nissen, Simon Lo, Miranda Bryant, Arsen Osipov, Andre Rogatko,
Mourad Tighiouart, Zhenqiu Liu, Nan Deng, Andrew Eugene Hendifar, Stephen Lawrence
Shiao. DNA repair deficiency, genomic instability and immune profiling in a phase 1 study of
locally advanced pancreatic cancer patients treated with veliparib, gemcitabine and
radiotherapy. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018
(suppl; abstr 4128). (PS)
99. Jonathan R. Strosberg, Edward M. Wolin, Beth A. Chasen, Matthew H. Kulke, David L
Bushnell, Martyn E. Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene
Hendifar, Laura Ravasi, Kjell E. Oberg, Philippe B. Ruszniewski, Eric Krenning. Clinical
outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate
vs. high dose octreotide in progressive midgut neuroendocrine tumors. 2018 ASCO Annual
Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018 (suppl; abstr 4102). (PS)
Andrew E. Hendifar, MD 43
100. Jonathan R. Strosberg, Edward M. Wolin, Beth A. Chasen, Matthew H. Kulke, David L
Bushnell, Martyn E. Caplin, Richard P. Baum, Timothy J. Hobday, Andrew Eugene
Hendifar, Maribel Lopera Sierra, Kjell E. Oberg, Philippe B. Ruszniewski, Eric Krenning.
First update on overall survival, progression-free survival, and health-related
time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose
octreotide in progressive midgut neuroendocrine tumors. 2018 ASCO Annual Meeting, June
1-6. Chicago, IL. J Clin Oncol 36, 2018 (suppl; abstr 4099). (PS)
101. Pamela L. Kunz, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre,
Carlos J. Suarez, James C. Yao, Matthew H. Kulke, Andrew Eugene Hendifar, James
Christopher Shanks, Manisha H. Shah, Mark Zalupski, Edmond L. Schmulbach, Diane
Lauren Reidy, Jonathan R. Strosberg, Peter J. O'Dwyer, Al Bowen Benson. A randomized
study of temozolomide or temozolomide and capecitabine in patients with advanced
pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group
(E2211). 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018
(suppl; abstr 4004). (OAS)
102. Subha Madhavan, Edik Matthew Blais, R Joseph Bender, Vincent M. Chung, Andrew
Eugene Hendifar, Sameh Mikhail, Maeve Aine Lowery, Davendra Sohal, Paula Raffin
Pohlmann, Kathleen N. Moore, Kai He, Bradley J. Monk, Robert L. Coleman, Thomas J.
Herzog, Emanuel Petricoin, David Charles Halverson, Michael J. Pishvaian. A
cloud-based virtual tumor board to facilitate treatment recommendations for patients with
advanced cancers. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36,
2018 (suppl; abstr 6508). (OAS)
103. Emanuel Petricoin, R Joseph Bender, David Charles Halverson, Lola Rahib, Andrew
Eugene Hendifar, Sameh Mikhail, Vincent M. Chung, Vincent J. Picozzi, Davendra
Sohal, Lynn McCormick Matrisian, Jonathan Robert Brody, Subha Madhavan, Michael J.
Pishvaian. Precision medicine for pancreatic cancer patients:preliminary results from the
know your tumor program. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin
Oncol 36, 2018 (suppl; abstr 4126). (PS)
104. Varun Yadav Roy, Andrew Eugene Hendifar. Portal hypertension and ascites in
pancreatic cancer. 2018 ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36,
2018 (suppl; abstr e16242).
105. Jun Gong, Michelle Guan, Cook-Wiens Galen, Brent K Larson, Jenny Zhou, Rishi Patel,
Isaac Lapite, Richard Tuli, Ronald B. Natale, Andrew Eugene Hendifar. Tumor
hyaluronan (HA) as a novel biomarker in non-small cell lung cancer (NSCLC). 2018
ASCO Annual Meeting, June 1-6. Chicago, IL. J Clin Oncol 36, 2018 (suppl; abstr
e24280).
106. Andrew E. Hendifar, Michelle Guan, Veronica Placencio, Theresa Zimmers. Focus on
pancreatic cancer cachexia: clinical trials in progress. 4th Cancer Cachexia Conference,
September 14-16. Philadelphia, PA.
Andrew E. Hendifar, MD 44
107. Ingrid He, Michael Luu, Veronica Placencio, Varun Roy, John David, Michelle Guan,
Richard Tuli, Andrew Hendifar. Palliative radiotherapy for skeletal-related events in
neuroendocrine tumors. NANETS Annual Multidisciplinary NET Disease Symposium,
October 4-6, 2018. Seattle, WA. (P)
108. TA Rich, K Clifton, A Grothey, A Hendifar, DH Henry, Y Kagawa, Y Nakamura, W
Okamoto, BR Tan, G Sherrill, T Yoshino, VM Raymond, Y Shiotsu, RB Lanman, V
Morris. RET rearrangements may arise following anti-EGFR therapy in advanced
colorectal cancer. 43rd ESMO Congress (ESMO 2018), October 19-23. Munich, Germany.
Ann Oncol 29, 2018 (suppl 8; abstr 482P). (PP)
109. T Macarulla Mercade, A Hendifar, C-P Li, M Reni, H Riess, MA Tempero, A Dueck, MF
Botteman, C Deshpande, E Lucas, DY Oh. Health-related quality of life (HRQoL) in
patients with early-stage pancreatic cancer (ESPC) receiving adjuvant or neoadjuvant
chemotherapy (A/NAC): A systematic literature review (SLR). 43rd ESMO Congress
(ESMO 2018), October 19-23. Munich, Germany. Ann Oncol 29, 2018 (suppl 8; abstr
741P) (PP)
110. E Van Cutsem, PG Corrie, MP Ducreux, D Sigal, V Sahai, D-Y Oh, A Bullock, Y-J Bang,
AD Baron, A Hendifar, C-P Li, P Philip, M Reni, M. Zalupski, L Zheng, C Berman, D.
Chondros, MA Tempero. HALO 109-301: Phase 3, randomized, double-blind,
placebo-controlled study of pegvorhyaluronidase alfa (PEGPH20) +
nab-paclitaxel/gemcitabine (AG) in patients with previously untreated hyaluronan
(HA)-high Stage IV pancreatic ductal adenocarcinoma (PDA). 43rd ESMO Congress
(ESMO 2018), October 19-23. Munich, Germany. Ann Oncol 29, 2018 (suppl 8; abstr
789TiP) (PP)
111. J Strosberg, A Hendifar, JC Yao, M Kulke, T O’Dorisio, M Caplin, RP Baum, P Kunz, T
Hobday, E Wolin, ES Mittra, K Oberg, P Ruszniewski, B Polack, B He, D Barton, P
Santaro, E Krenning. Impact of liver tumor burden on therapeutic effect of 177Lu-Dotatate
treatment in NETTER-1 study. 43rd ESMO Congress (ESMO 2018), October 19-23.
Munich, Germany. Ann Oncol 29, 2018 (suppl 8; abstr 1316P) (PP)
112. V Roy, G Cook-Wiens, M Guan, V Placencio, A Torosian, J Gong, I He, A Osipov, R Tuli,
A Hendifar. Portal hypertension in pancreatic cancer is associated with radiation therapy.
49th American Pancreatic Association (APA) Annual Meeting, October 31-November 3,
2018. Miami, Beach. FL. (PP)